1
|
Crew KD, Anderson GL, Arnold KB, Stieb AP, Amenta JN, Collins N, Law CW, Pruthi S, Sandoval-Leon A, Bertoni D, Grosse Perdekamp MT, Colonna S, Krisher S, King T, Yee LD, Ballinger TJ, Braun-Inglis C, Mangino D, Wisinski KB, DeYoung CA, Ross M, Floyd J, Kaster A, Vander Walde L, Saphner T, Zarwan C, Lo S, Graham C, Conlin A, Yost K, Agnese D, Jernigan C, Hershman DL, Neuhouser ML, Arun B, Kukafka R. Making informed choices on incorporating chemoprevention into carE (MiCHOICE, SWOG 1904): Design and methods of a cluster randomized controlled trial. Contemp Clin Trials 2024:107564. [PMID: 38704119 DOI: 10.1016/j.cct.2024.107564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2023] [Revised: 04/15/2024] [Accepted: 05/01/2024] [Indexed: 05/06/2024]
Abstract
INTRODUCTION Women with atypical hyperplasia (AH) or lobular carcinoma in situ (LCIS) have a significantly increased risk of breast cancer, which can be substantially reduced with antiestrogen therapy for chemoprevention. However, antiestrogen therapy for breast cancer risk reduction remains underutilized. Improving knowledge about breast cancer risk and chemoprevention among high-risk patients and their healthcare providers may enhance informed decision-making about this critical breast cancer risk reduction strategy. METHODS/DESIGN We are conducting a cluster randomized controlled trial to evaluate the effectiveness and implementation of patient and provider decision support tools to improve informed choice about chemoprevention among women with AH or LCIS. We have cluster randomized 26 sites across the U.S. through the SWOG Cancer Research Network. A total of 415 patients and 200 healthcare providers are being recruited. They are assigned to standard educational materials alone or combined with the web-based decision support tools. Patient-reported and clinical outcomes are assessed at baseline, after a follow-up visit at 6 months, and yearly for 5 years. The primary outcome is chemoprevention informed choice after the follow-up visit. Secondary endpoints include other patient-reported outcomes, such as chemoprevention knowledge, decision conflict and regret, and self-reported chemoprevention usage. Barriers and facilitators to implementing decision support into clinic workflow are assessed through patient and provider interviews at baseline and mid-implementation. RESULTS/DISCUSSION With this hybrid effectiveness/implementation study, we seek to evaluate if a multi-level intervention effectively promotes informed decision-making about chemoprevention and provide valuable insights on how the intervention is implemented in U.S. CLINICAL SETTINGS TRIAL REGISTRATION NCT04496739.
Collapse
Affiliation(s)
- K D Crew
- Columbia University Irving Medical Center, New York, NY, USA.
| | - G L Anderson
- SWOG Statistics and Data Management Center, Seattle, WA, USA
| | - K B Arnold
- SWOG Statistics and Data Management Center, Seattle, WA, USA
| | - A P Stieb
- Columbia University Irving Medical Center, New York, NY, USA
| | - J N Amenta
- Columbia University Irving Medical Center, New York, NY, USA
| | - N Collins
- Columbia University Irving Medical Center, New York, NY, USA
| | - C W Law
- Columbia University Irving Medical Center, New York, NY, USA
| | - S Pruthi
- Mayo Clinic, Rochester, MN, United States of America
| | - A Sandoval-Leon
- Miami Cancer Institute at Baptist Health South Florida, Miami, FL, USA
| | - D Bertoni
- Good Samaritan Hospital Corvallis, Corvallis, OR , USA
| | | | - S Colonna
- Huntsman Cancer Institute / University of Utah Medical Center, Salt Lake City, UT, USA
| | - S Krisher
- Holy Redeemer Hospital and Medical Center, Meadowbrook, PA, USA
| | - T King
- Dana-Farber Brigham Cancer Center, Brigham and Women's Hospital, Boston, MA, USA
| | - L D Yee
- City of Hope Comprehensive Cancer Center, Duarte, CA, USA
| | - T J Ballinger
- Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, USA
| | | | - D Mangino
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - K B Wisinski
- University of Wisconsin Carbone Cancer Center, Madison, WI, USA
| | | | - M Ross
- Virginia Commonwealth University, Richmond, VA, USA
| | - J Floyd
- Cancer Care Specialists of Illinois, Heartland NCORP, Decatur, IL, USA
| | - A Kaster
- Sanford Roger Maris Cancer Center, Fargo, ND, United States of America
| | - L Vander Walde
- Baptist Memorial Health Care, Memphis, TN, United States of America
| | | | - C Zarwan
- Lahey Hospital & Medical Center, Burlington, MA, USA
| | - S Lo
- Loyola University Stritch School of Medicine, Maywood, IL, USA
| | - C Graham
- Emory University Hospital/Winship Cancer Institute, Atlanta, GA, USA
| | - A Conlin
- Providence Cancer Institute, Portland, OR, USA
| | - K Yost
- Cancer Research Consortium of West Michigan NCORP, Kalamazoo, MI, USA
| | - D Agnese
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - C Jernigan
- Columbia University Irving Medical Center, New York, NY, USA
| | - D L Hershman
- Columbia University Irving Medical Center, New York, NY, USA
| | | | - B Arun
- The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - R Kukafka
- Columbia University Irving Medical Center, New York, NY, USA
| |
Collapse
|
2
|
Jones T, Trivedi MS, Jiang X, Silverman T, Underhill M, Chung WK, Kukafka R, Crew KD. Racial and Ethnic Differences in BRCA1/2 and Multigene Panel Testing Among Young Breast Cancer Patients. J Cancer Educ 2021; 36:463-469. [PMID: 31802423 PMCID: PMC7293107 DOI: 10.1007/s13187-019-01646-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Genetic testing for hereditary breast and ovarian cancer (HBOC) is recommended for breast cancer patients diagnosed at age ≤ 50 years. Our objective was to examine racial/ethnic differences in genetic testing frequency and results among diverse breast cancer patients. A retrospective cohort study among women diagnosed with breast cancer at age ≤ 50 years from January 2007 to December 2017 at Columbia University in New York, NY. Among 1503 diverse young breast cancer patients, nearly half (46.2%) completed HBOC genetic testing. Genetic testing completion was associated with younger age, family history of breast cancer, and earlier stage, but not race/ethnicity or health insurance status. Blacks had the highest frequency of pathogenic/likely pathogenic (P/LP) variants (18.6%), and Hispanics and Asians had the most variants of uncertain significance (VUS), 19.0% and 21.9%, respectively. The percentage of women undergoing genetic testing increased over time from 15.3% in 2007 to a peak of 72.8% in 2015. Over the same time period, there was a significant increase in P/LP and VUS results. Due to uncertainty about the clinical implications of P/LP variants in moderate penetrance genes and VUSs, our findings underscore the need for targeted genetic counseling education, particularly among young minority breast cancer patients.
Collapse
Affiliation(s)
- T Jones
- Florida Atlantic University, Christine E. Lynn College of Nursing, Boca Raton, FL, 33431, USA.
| | - M S Trivedi
- Columbia University Irving Medical Center, New York, NY, 10032, USA
| | - X Jiang
- Columbia University Irving Medical Center, New York, NY, 10032, USA
| | - T Silverman
- Columbia University Irving Medical Center, New York, NY, 10032, USA
| | - M Underhill
- Dana Farber Cancer Institute, Boston, MA, 02215, USA
| | - W K Chung
- Columbia University Irving Medical Center, New York, NY, 10032, USA
| | - R Kukafka
- Columbia University Irving Medical Center, New York, NY, 10032, USA
| | - K D Crew
- Columbia University Irving Medical Center, New York, NY, 10032, USA
| |
Collapse
|
3
|
Trivedi MS, Jones T, Jiang X, Underhill ML, Bose S, Silverman T, Chung WK, Kukafka R, Crew KD. Abstract P5-09-01: Racial/ethnic differences in BRCA1/2 and multigene panel testing among young breast cancer patients. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-09-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast cancer (BC) patients diagnosed at age 50 and under are recommended to have germline genetic testing for hereditary BC due to a high likelihood of carrying a pathogenic mutation in a moderate or high penetrance risk gene. Completion of genetic testing among racial/ethnic minorities, particularly multigene panel testing, is understudied. We examined predictors of completion of BRCA1/2 and multigene panel testing among women with early onset BC and assessed racial/ethnic differences in genetic testing completion and results.
Methods: We performed a retrospective cohort study of 1370 BC patients diagnosed at <50 years of age at Columbia University Medical Center (CUMC) from January 2007-December 2016.Data on socio-demographics, clinical factors, and genetic testing completion and results were collected from the medical record. We conducted descriptive statistics and univariate and multivariable logistic regression models.
Results: Our study population had a median age of 44 years (range, 19-50); 44% non-Hispanic white, 24% Hispanic, 13% non-Hispanic black, 10% Asian, 9% other; 61% private insurance, 22% Medicaid, 17% other. Nearly half of the women (N=607; 44.3%) had genetic testing performed. In the multivariable regression model, genetic testing completion was less likely with increasing age at diagnosis (odds ratio [OR]=0.93; 95% confidence interval [CI]=0.91-0.95) and stage 0 or 4 BC compared to stage 1 (OR=0.67; 95% CI=0.46-0.97 and OR=0.35; 95% CI=0.19-0.64, respectively). Completion of genetic testing was more likely with a family history of BC (OR=5.55; 95% CI=3.92-7.87). Genetic testing completion did not vary by race/ethnicity or insurance coverage. Across all racial/ethnic groups, the frequency of pathogenic/likely pathogenic variants identified was 13.0% and 10.5% had at least 1 variant of uncertain significance (VUS). The highest VUS frequency was among Asians (21.2%). The percentage of women undergoing genetic testing increased over time from 18.5% in 2007 and reached a peak of 69.3% in 2015. From 2007 to 2016, the percentage of pathogenic/likely pathogenic variants detected increased from 3.4% to 9.1% and the VUS frequency rose from 3.4% to 13.3% with increasing use of panel testing.
Frequency of pathogenic variants and VUS among women ≤ 50 years diagnosed with BC at CUMC (2007-2016) Pathogenic variantsVUSTotal81 (5.9%)74 (5.4%)BRCA144 (3.2%)10 (0.7%)BRCA221 (1.5%)10 (0.7%)ATM3 (0.2%)9 (0.6%)CHEK23 (0.2%)8 (0.5%)Other variants detected in: APC, BARD1, BRIP1, CDH1, CDKN2A, MEN1, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PHOX2B, PMS2, POLE, PTEN, RAD50, RAD51C, SDHA, STK11, TP53
Conclusions and Relevance: Nearly half of the women with early onset BC had genetic testing. We did not observe disparities in genetic testing by race/ethnicity or insurance coverage. Genetic testing completion, as well as the frequency of pathogenic/likely pathogenic variants and VUS detection, increased over time as panel testing replaced BRCA1/2 testing. Counseling on the likelihood of obtaining uncertain results should be provided to all patients undergoing hereditary BC genetic testing, particularly to racial/ethnic minorities.
Citation Format: Trivedi MS, Jones T, Jiang X, Underhill ML, Bose S, Silverman T, Chung WK, Kukafka R, Crew KD. Racial/ethnic differences in BRCA1/2 and multigene panel testing among young breast cancer patients [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-09-01.
Collapse
Affiliation(s)
- MS Trivedi
- Columbia University Medical Center, New York, NY; Florida Atlantic University, Christine E. Lynn College of Nursing, Boca Raton, FL; Dana Farber Cancer Institute, Boston, MA
| | - T Jones
- Columbia University Medical Center, New York, NY; Florida Atlantic University, Christine E. Lynn College of Nursing, Boca Raton, FL; Dana Farber Cancer Institute, Boston, MA
| | - X Jiang
- Columbia University Medical Center, New York, NY; Florida Atlantic University, Christine E. Lynn College of Nursing, Boca Raton, FL; Dana Farber Cancer Institute, Boston, MA
| | - ML Underhill
- Columbia University Medical Center, New York, NY; Florida Atlantic University, Christine E. Lynn College of Nursing, Boca Raton, FL; Dana Farber Cancer Institute, Boston, MA
| | - S Bose
- Columbia University Medical Center, New York, NY; Florida Atlantic University, Christine E. Lynn College of Nursing, Boca Raton, FL; Dana Farber Cancer Institute, Boston, MA
| | - T Silverman
- Columbia University Medical Center, New York, NY; Florida Atlantic University, Christine E. Lynn College of Nursing, Boca Raton, FL; Dana Farber Cancer Institute, Boston, MA
| | - WK Chung
- Columbia University Medical Center, New York, NY; Florida Atlantic University, Christine E. Lynn College of Nursing, Boca Raton, FL; Dana Farber Cancer Institute, Boston, MA
| | - R Kukafka
- Columbia University Medical Center, New York, NY; Florida Atlantic University, Christine E. Lynn College of Nursing, Boca Raton, FL; Dana Farber Cancer Institute, Boston, MA
| | - KD Crew
- Columbia University Medical Center, New York, NY; Florida Atlantic University, Christine E. Lynn College of Nursing, Boca Raton, FL; Dana Farber Cancer Institute, Boston, MA
| |
Collapse
|
4
|
Accordino MK, Lin A, Wright JD, Trivedi MS, Kalinsky K, Crew KD, Hershman DL. Abstract P1-20-02: Incidence of hyperglycemia in non-diabetic patients with early-stage breast cancer treated with chemotherapy. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-20-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: There are shared risk factors between breast cancer (BC) and diabetes mellitus (DM). BC treatments including chemotherapy given in combination with glucocorticoids can induce hyperglycemia and steroid related DM. Patients with DM are at increased risk of developing chemotherapy related toxicities such as chemotherapy induced peripheral neuropathy (CIPN) compared to those without DM. The incidence of hyperglycemia during chemotherapy in non-diabetic patients with early-stage breast cancer is unknown.
Methods: We performed a retrospective analysis of non-diabetic women with stage I-III breast cancer treated with chemotherapy at Columbia University Medical Center from 9/1/2016-8/31/2017 to evaluate hyperglycemia incidence during chemotherapy and up to six months after chemotherapy completion. Eligible patients were identified in the electronic health record (EHR) by ICD9 and 10 codes (ICD9 174.x and ICD10 C50.x) and a record of chemotherapy administration. Non-diabetic patients were defined by chart review as no recorded history of diabetes and no receipt of a diabetes medication in the EHR. Breast cancer stage was determined by chart review. Glucose values were recorded prior to chemotherapy, during chemotherapy, and for six-months after chemotherapy completion. We defined hyperglycemia as a glucose value of ≥200 mg/dl. Median time to hyperglycemia was also calculated.
Results: We identified 82 eligible patients. The majority of patients received dexamethasone during their chemotherapy course (79 patients, 96.3%). The most frequent chemotherapy regimen was doxorubicin/cyclophosphamide and paclitaxel (32 patients, 39.0%). At baseline, 20 patients (24.4%) had a normal body mass index (BMI), 27 patients (32.9%) were overweight, and 31 patients (37.8%) were obese. Hyperglycemia occurred in 8 patients (9.8%) after initiation of chemotherapy. Among patients with hyperglycemia, the maximum blood glucose was between 200-299 mg/dl in seven patients (87.5%), and between 500-599 in one patient (12.5%). The median time to hyperglycemia was 84 days. Among patients who did not experience hyperglycemia, the maximum blood glucose was between 140-159 mg/dl in six patients (8.1%), between 160-179 mg/dl in eight patients (10.8%), and between 180-199 mg/dl in three patients (4.1%). Three patients were diagnosed with DM following chemotherapy completion.
Conclusion: Hyperglycemia occurred in almost 10% of non-diabetic patients who received chemotherapy for early-stage breast cancer. Additionally, over 30% of patients had a blood glucose of 140 mg/dl or higher after chemotherapy initiation. The impact of hyperglycemia on the development of chemotherapy related toxicities in this group is unknown. Future research is needed to identify effective interventions for glucose control during chemotherapy, and to determine if glucose control during treatment can reduce the risk of chemotherapy related toxicities, specifically CIPN.
Citation Format: Accordino MK, Lin A, Wright JD, Trivedi MS, Kalinsky K, Crew KD, Hershman DL. Incidence of hyperglycemia in non-diabetic patients with early-stage breast cancer treated with chemotherapy [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-20-02.
Collapse
Affiliation(s)
- MK Accordino
- Columbia University Medical Center, New York, NY
| | - A Lin
- Columbia University Medical Center, New York, NY
| | - JD Wright
- Columbia University Medical Center, New York, NY
| | - MS Trivedi
- Columbia University Medical Center, New York, NY
| | - K Kalinsky
- Columbia University Medical Center, New York, NY
| | - KD Crew
- Columbia University Medical Center, New York, NY
| | - DL Hershman
- Columbia University Medical Center, New York, NY
| |
Collapse
|
5
|
Fenn KM, Maurer MA, Lee SM, Crew KD, Trivedi MS, Accordino MK, Hershman DL, Kalinsky K. Abstract P6-18-35: A phase 1 study of erlotinib and metformin in advanced triple negative breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-18-35] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The epidermal growth factor receptor (EGFR) is frequently overexpressed in triple negative breast cancer (TNBC). However, EGFR inhibitors have not shown efficacy as monotherapy in TNBC. One strategy for overcoming resistance to EGFR inhibition is concomitant inhibition of downstream signaling. Metformin is a LKB1-dependent AMPK activator that inhibits both MAPK and AKT signaling. The combination of the EGFR inhibitor erlotinib and metformin synergistically induces apoptosis in TNBC cell lines and decreases tumor burden in PTEN-null EGFR-amplified mouse xenograft models. We evaluated the combination of erlotinib and metformin in a phase 1 study of patients with advanced TNBC.
Methods: Patients with advanced TNBC who had received at least one prior line of therapy for metastatic disease were eligible. Erlotinib dose was fixed at 150mg daily. Metformin dose escalation was planned according to a 3+3 design, beginning at 850mg BID and escalating to 850mg TID. One de-escalation to 500mg BID was allowed. Dose-limiting toxicities (DLT) were assessed during the first five weeks of therapy. The primary objectives were to determine the maximum tolerated dose (MTD) of metformin with fixed dose erlotinib and to determine the potential for clinical benefit. Secondary endpoints were response rate, stable disease rate, and progression free survival. Pre- and on-treatment skin biopsies were collected to determine the effect of the study drugs on their respective cell signaling targets, particularly EGFR, AMPK, and mTOR.
Results: Between March 2013 and May 2015, nine patients were screened and eight were enrolled. Median age was 48 years (range 37-79). Median number of prior therapies for metastatic disease was 2.5 (range 1-6). No DLT events were reported in either of the dose escalation cohorts during the DLT assessment period. AEs occurring in three or more patients and all grade III AEs are reported in Table 1. Grade III diarrhea despite maximum supportive care required dose reduction of metformin from 850mg TID to 850mg BID in one patient. Grade III rash led to study withdrawal in one patient. No grade IV AEs were reported. Per RECIST v1.1, the best observed response was stable disease in two patients (25%). Median time on study was 2.0 months (range 1.2-3.0). Skin biopsy marker assessment is ongoing and will be reported.
Conclusion: The combination of erlotinib and metformin was generally well tolerated in a population of pre-treated metastatic TNBC patients. No unexpected toxicities occurred. While no responses were achieved, stable disease was observed in patients who received this non-chemotherapy combination.
Adverse EventsEventMetformin 850mg BID n=3Metformin 850mg TID n=5All patients n=8 Number of patients (percent) All gradesGrade IIIAll gradesGrade IIIAll gradesGrade IIIRash3 (100)1 (33.3)5 (100)08 (100)1 (12.5)Diarrhea3 (100)05 (100)2 (40.0)8 (100)2 (25.0)Weight loss1 (33.3)05 (100)06 (75.0)0Dry skin1 (33.3)05 (100)06 (75.0)0Nausea2 (66.7)03 (60.0)05 (62.5)0Vomiting1 (33.3)03 (60.0)04 (50.0)0Dry mouth1 (33.3)03 (60.0)04 (50.0)0Dysgeusia1 (33.3)02 (40.0)03 (37.5)0Increased creatinine2 (66.7)01 (20.0)03 (37.5)0Fatigue1 (33.3)02 (40.0)03 (37.5)0Anorexia1 (33.3)02 (40.0)03 (37.5)0Hyponatremia1 (33.3)1 (33.3)001 (12.5)1 (12.5)
Citation Format: Fenn KM, Maurer MA, Lee SM, Crew KD, Trivedi MS, Accordino MK, Hershman DL, Kalinsky K. A phase 1 study of erlotinib and metformin in advanced triple negative breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-18-35.
Collapse
Affiliation(s)
- KM Fenn
- Columbia University Irving Medical Center, New York, NY; Mailman School of Public Health, Columbia University, New York, NY
| | - MA Maurer
- Columbia University Irving Medical Center, New York, NY; Mailman School of Public Health, Columbia University, New York, NY
| | - SM Lee
- Columbia University Irving Medical Center, New York, NY; Mailman School of Public Health, Columbia University, New York, NY
| | - KD Crew
- Columbia University Irving Medical Center, New York, NY; Mailman School of Public Health, Columbia University, New York, NY
| | - MS Trivedi
- Columbia University Irving Medical Center, New York, NY; Mailman School of Public Health, Columbia University, New York, NY
| | - MK Accordino
- Columbia University Irving Medical Center, New York, NY; Mailman School of Public Health, Columbia University, New York, NY
| | - DL Hershman
- Columbia University Irving Medical Center, New York, NY; Mailman School of Public Health, Columbia University, New York, NY
| | - K Kalinsky
- Columbia University Irving Medical Center, New York, NY; Mailman School of Public Health, Columbia University, New York, NY
| |
Collapse
|
6
|
Trivedi MS, Samimi G, Wright JD, Holcomb K, Garber JE, Horowitz NS, Arber N, Friedman E, Wenham RM, House M, Parnes H, Lee JJ, Abutaseh S, Vornik LA, Heckman-Stoddard BM, Brown PH, Crew KD. Abstract OT2-09-01: Pilot study of denosumab in BRCA1/2 mutation carriers scheduling for risk-reducing salpingo-oophorectomy. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot2-09-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Denosumab is a monoclonal antibody that inhibits RANKL and is approved for the prevention of fractures in patients with osteoporosis or bone metastases. The RANKL signaling pathway is also involved in BRCA1-associated mammary tumorigenesis via a progesterone-induced paracrine effect of RANKL on luminal progenitor cells. Pre-clinical studies have demonstrated that RANKL inhibition resulted in reduced proliferation of mammary tumors. Early findings from an ongoing pre-surgical study demonstrated that denosumab treatment resulted in decreased Ki67 proliferation index in benign breast tissue. Based on these data, denosumab is being pursued as a potential preventive agent for breast cancer in BRCA1 mutation carriers. While promising, the effect of RANKL inhibition on gynecologic tissues such as the ovaries and fallopian tubes, in which progesterone has a protective effect, is unknown.
Trial design: We will conduct a multicenter, open-label randomized pilot study of presurgical administration of denosumab versus no treatment in premenopausal women with BRCA1/2 mutations undergoing risk-reducing salpingo-oophorectomy (RRSO). A total of 60 women will be randomized 1:1 to Arm 1) 3-4 doses of 120 mg denosumab subcutaneously every 4 weeks or Arm 2) No treatment. Participants will be stratified by 1) BRCA1 versus BRCA2 mutation status and 2) Use of hormonal contraceptives within the past 3 months (yes/no). Assuming a 10% unevaluable rate, we expect to have 54 evaluable participants (27 per arm).
Eligibility criteria: 1) Premenopausal women (defined as < 3 months since last menstrual period OR serum follicle-stimulating hormone (FSH) < 20 mIU/mL), age > 18 years; 2) Documented germline pathogenic mutation or likely pathogenic variant in the BRCA1 or BRCA2 gene; 3) Plan for RRSO with or without hysterectomy; 4) ECOG performance status ≤ 1 (Karnofsky ≥ 70%); 5) Normal organ and marrow function; 6) Negative pregnancy test and use of adequate contraception; 7) Willingness to take supplemental oral calcium and vitamin D3; 8) Dental examination within 6 months of enrollment and no evidence of active dental issues; 9) Ability to understand and willingness to provide informed consent.
Specific aims: Our primary objective is to compare the effect of denosumab to no treatment on Ki67 expression in the fimbrial end of the fallopian tube. Secondary objectives are to assess Ki67 in ovary and endometrium; cleaved caspase-3, RANK/RANKL, ER/PR, CD44, and STAT3/pSTAT3 expression in fallopian tube, ovary, and endometrium; gene expression profiling in the fallopian tube and ovary; serum markers (progesterone, estradiol, C-terminal telopeptide) and denosumab levels; and toxicity.
Statistical methods: The primary endpoint is post-treatment Ki67 expression in the fimbrial end of the fallopian tube in the denosumab arm compared to the no treatment arm. Assuming a standard deviation of 5.0%, we will have 82% power to detect a 4.0% absolute difference (or effect size of 0.8) in Ki67 proliferation index between the denosumab and no treatment groups by applying a 2-sample t-test at a 0.05 significance level.
Target accrual: 60 participants, to be activated in Summer 2018.
Citation Format: Trivedi MS, Samimi G, Wright JD, Holcomb K, Garber JE, Horowitz NS, Arber N, Friedman E, Wenham RM, House M, Parnes H, Lee JJ, Abutaseh S, Vornik LA, Heckman-Stoddard BM, Brown PH, Crew KD. Pilot study of denosumab in BRCA1/2 mutation carriers scheduling for risk-reducing salpingo-oophorectomy [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT2-09-01.
Collapse
Affiliation(s)
- MS Trivedi
- Columbia University Medical Center, New York, NY; National Cancer Institute, NIH, Bethesda, MD; Weill Cornell Medical Center, New York, NY; Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Chaim Sheba Medical Center, Tel-Hashomer, Israel; Moffitt Cancer Center, Tampa, FL; University of Texas MD Anderson Cancer Center, Houston, TX
| | - G Samimi
- Columbia University Medical Center, New York, NY; National Cancer Institute, NIH, Bethesda, MD; Weill Cornell Medical Center, New York, NY; Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Chaim Sheba Medical Center, Tel-Hashomer, Israel; Moffitt Cancer Center, Tampa, FL; University of Texas MD Anderson Cancer Center, Houston, TX
| | - JD Wright
- Columbia University Medical Center, New York, NY; National Cancer Institute, NIH, Bethesda, MD; Weill Cornell Medical Center, New York, NY; Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Chaim Sheba Medical Center, Tel-Hashomer, Israel; Moffitt Cancer Center, Tampa, FL; University of Texas MD Anderson Cancer Center, Houston, TX
| | - K Holcomb
- Columbia University Medical Center, New York, NY; National Cancer Institute, NIH, Bethesda, MD; Weill Cornell Medical Center, New York, NY; Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Chaim Sheba Medical Center, Tel-Hashomer, Israel; Moffitt Cancer Center, Tampa, FL; University of Texas MD Anderson Cancer Center, Houston, TX
| | - JE Garber
- Columbia University Medical Center, New York, NY; National Cancer Institute, NIH, Bethesda, MD; Weill Cornell Medical Center, New York, NY; Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Chaim Sheba Medical Center, Tel-Hashomer, Israel; Moffitt Cancer Center, Tampa, FL; University of Texas MD Anderson Cancer Center, Houston, TX
| | - NS Horowitz
- Columbia University Medical Center, New York, NY; National Cancer Institute, NIH, Bethesda, MD; Weill Cornell Medical Center, New York, NY; Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Chaim Sheba Medical Center, Tel-Hashomer, Israel; Moffitt Cancer Center, Tampa, FL; University of Texas MD Anderson Cancer Center, Houston, TX
| | - N Arber
- Columbia University Medical Center, New York, NY; National Cancer Institute, NIH, Bethesda, MD; Weill Cornell Medical Center, New York, NY; Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Chaim Sheba Medical Center, Tel-Hashomer, Israel; Moffitt Cancer Center, Tampa, FL; University of Texas MD Anderson Cancer Center, Houston, TX
| | - E Friedman
- Columbia University Medical Center, New York, NY; National Cancer Institute, NIH, Bethesda, MD; Weill Cornell Medical Center, New York, NY; Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Chaim Sheba Medical Center, Tel-Hashomer, Israel; Moffitt Cancer Center, Tampa, FL; University of Texas MD Anderson Cancer Center, Houston, TX
| | - RM Wenham
- Columbia University Medical Center, New York, NY; National Cancer Institute, NIH, Bethesda, MD; Weill Cornell Medical Center, New York, NY; Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Chaim Sheba Medical Center, Tel-Hashomer, Israel; Moffitt Cancer Center, Tampa, FL; University of Texas MD Anderson Cancer Center, Houston, TX
| | - M House
- Columbia University Medical Center, New York, NY; National Cancer Institute, NIH, Bethesda, MD; Weill Cornell Medical Center, New York, NY; Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Chaim Sheba Medical Center, Tel-Hashomer, Israel; Moffitt Cancer Center, Tampa, FL; University of Texas MD Anderson Cancer Center, Houston, TX
| | - H Parnes
- Columbia University Medical Center, New York, NY; National Cancer Institute, NIH, Bethesda, MD; Weill Cornell Medical Center, New York, NY; Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Chaim Sheba Medical Center, Tel-Hashomer, Israel; Moffitt Cancer Center, Tampa, FL; University of Texas MD Anderson Cancer Center, Houston, TX
| | - JJ Lee
- Columbia University Medical Center, New York, NY; National Cancer Institute, NIH, Bethesda, MD; Weill Cornell Medical Center, New York, NY; Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Chaim Sheba Medical Center, Tel-Hashomer, Israel; Moffitt Cancer Center, Tampa, FL; University of Texas MD Anderson Cancer Center, Houston, TX
| | - S Abutaseh
- Columbia University Medical Center, New York, NY; National Cancer Institute, NIH, Bethesda, MD; Weill Cornell Medical Center, New York, NY; Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Chaim Sheba Medical Center, Tel-Hashomer, Israel; Moffitt Cancer Center, Tampa, FL; University of Texas MD Anderson Cancer Center, Houston, TX
| | - LA Vornik
- Columbia University Medical Center, New York, NY; National Cancer Institute, NIH, Bethesda, MD; Weill Cornell Medical Center, New York, NY; Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Chaim Sheba Medical Center, Tel-Hashomer, Israel; Moffitt Cancer Center, Tampa, FL; University of Texas MD Anderson Cancer Center, Houston, TX
| | - BM Heckman-Stoddard
- Columbia University Medical Center, New York, NY; National Cancer Institute, NIH, Bethesda, MD; Weill Cornell Medical Center, New York, NY; Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Chaim Sheba Medical Center, Tel-Hashomer, Israel; Moffitt Cancer Center, Tampa, FL; University of Texas MD Anderson Cancer Center, Houston, TX
| | - PH Brown
- Columbia University Medical Center, New York, NY; National Cancer Institute, NIH, Bethesda, MD; Weill Cornell Medical Center, New York, NY; Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Chaim Sheba Medical Center, Tel-Hashomer, Israel; Moffitt Cancer Center, Tampa, FL; University of Texas MD Anderson Cancer Center, Houston, TX
| | - KD Crew
- Columbia University Medical Center, New York, NY; National Cancer Institute, NIH, Bethesda, MD; Weill Cornell Medical Center, New York, NY; Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Chaim Sheba Medical Center, Tel-Hashomer, Israel; Moffitt Cancer Center, Tampa, FL; University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
7
|
Wu R, Crew KD. Abstract P1-10-04: Racial and ethnic differences in weight gain during and after chemotherapy among women with early-stage breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-10-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Objective
Clinically significant weight gain of ≥5% from baseline has been commonly reported during chemotherapy treatment for early stage breast cancer and persisting after completion. Based on the known poorer outcomes associated with weight gain after a breast cancer diagnosis, we evaluated differential weight gain by race/ethnicity as a potential explanation for disparities in breast cancer clinical outcomes among racial/ethnic minorities compared to non-Hispanic white women.
Methods
We conducted a retrospective cohort study among women diagnosed with stage I-III breast cancer between 2007 and 2016, who received chemotherapy at Columbia University Medical Center (CUMC) in New York, NY. We extracted data on demographics, clinical characteristics, chemotherapy regimens, and height/weight from the electronic health records. Our main exposure variable of interest was race/ethnicity. The outcome variable was dichotomized as ≥5% weight gain or stable weight (defined as <5% weight gain or loss/≥5% weight loss) from baseline at 3, 6, 12, and 18 months after initiating chemotherapy. We used multinomial logistic regression analyses to determine the association between race/ethnicity and weight gain before and after adjusting for confounders.
Results
Among 789 evaluable women, median age was 55 years (range, 19-92) and the study cohort was racially/ethnically diverse: 39.8% non-Hispanic white, 30.4% Hispanic, 18.0% non-Hispanic black, 10.4% Asian, and 1.4% other. Mean baseline body mass index (BMI) was highest among black women (30.7 kg/m2 ± 7.0), followed by Hispanic (29.4 kg/m2 ± 5.2), non-Hispanic white (27.9 kg/m2 ± 6.9), and Asian (25.5 kg/m2 ± 5.4) women. The proportion of women with ≥5% weight gain increased over time with 13.6% at 3 months, 15.2% at 6 months, 19.0% at 12 months, and 23.6% at 18 months. Compared to non-Hispanic whites, Asian women had a 63% lower odds of ≥5% weight gain (95% Confidence Interval [CI]: 0.15-0.92) at 3 months after initiating chemotherapy. No statistically significant associations were found between other racial/ethnic groups and ≥5% weight gain. Factors associated with weight gain after chemotherapy included younger age at diagnosis, lower baseline BMI, longer duration of chemotherapy, and having Medicaid insurance coverage.
Conclusions
Race/ethnicity was not significantly associated with weight gain after chemotherapy among women with early stage breast cancer. Socioeconomic status (SES) rather than race/ethnicity may be a contributing factor in disparities in weight gain and breast cancer clinical outcomes. Future weight loss programs should target younger, pre-menopausal women and those with lower SES.
Citation Format: Wu R, Crew KD. Racial and ethnic differences in weight gain during and after chemotherapy among women with early-stage breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-10-04.
Collapse
Affiliation(s)
- R Wu
- Columbia University Medical Center, NY, NY
| | - KD Crew
- Columbia University Medical Center, NY, NY
| |
Collapse
|
8
|
Henry NL, Unger JM, Till C, Schott AF, Crew KD, Lew DL, Fisch MJ, Moinpour CM, Wade JL, Hershman DL. Abstract P1-11-04: Association between body mass index (BMI) and response to duloxetine for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-11-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: AIMSS occurs often in women treated with AI therapy for early stage breast cancer and can negatively impact adherence and persistence with therapy. Duloxetine is a serotonin norepinephrine reuptake inhibitor used to treat mood disorders and chronic pain. In SWOG S1202, patients with AIMSS treated with duloxetine reported statistically significant improvement in pain by 12 weeks compared to placebo. Obesity is a predictor of increased likelihood of developing AIMSS, and a prior study of omega 3 fatty acid versus placebo for AIMSS showed a potential differential response to therapy by BMI. In this exploratory analysis of S1202, we investigated the association between baseline BMI and response to therapy.
Methods: In S1202, 299 postmenopausal women with stage I-III hormone receptor-positive breast cancer on AI therapy who developed new or worsening average pain of 4-10 on a numerical rating scale were enrolled, randomized 1:1 to duloxetine or placebo with randomization stratified by baseline pain (4-6 vs. 7-10) and prior taxane therapy (yes vs. no). Patients were treated for 12 weeks. Patient-reported outcomes including Brief Pain Inventory (BPI) were obtained at baseline and weeks 2, 6, 12, and 24. Patients were categorized into BMI<30 kg/m2 (non-obese) or BMI≥30 kg/m2 (obese). The pre-specified aim of this secondary analysis was to examine whether the effect of intervention on BPI average pain at 12 weeks differed between obese and non-obese patients. Multiple linear regression was used, adjusting for the stratification factors and the baseline score. We tested whether the interaction of BMI status and intervention effect was statistically significant at α=.05.
Results: 289 patients were eligible for the analysis, 54% of whom were obese. The cohorts were well balanced other than by race. The difference by intervention arm in the 12-week mean BPI scores between baseline and follow-up scores was substantially different for the obese versus non-obese cohorts. In the patients with BMI<30, the reduction in observed mean average pain score was similar in the duloxetine- and placebo-treated patients (-2.46 points vs. -2.34 points, p=.75). In contrast, in the patients with BMI≥30 the reduction in pain score was statistically significantly greater for the duloxetine-treated compared to the placebo-treated patients (-2.73 points vs. -1.64 points, p=.003; interaction p-value=.02). Differences in intervention effects between obese and non-obese groups were even stronger at 2-weeks (interaction p-value=.001) and 6-weeks (interaction p-value<.0001). Similar findings were evident for other pain-related patient-reported outcomes.
Conclusions: In the placebo-controlled S1202 trial, obese patients with AIMSS obtained more analgesic benefit from duloxetine. Additional studies are warranted to determine the biologic basis for these findings, such as a different mechanism underlying development of AIMSS or pain expression in patients with obesity, or other confounding variables related to analgesic response to duloxetine relative to placebo.
Support: NIH/NCI grants CA189974, CA189821, CA180820; and in part by Damon Runyon-Lilly Clinical Investigator Award #CI-53-10 [to NLH], and in part by Lilly USA, LLC.
Citation Format: Henry NL, Unger JM, Till C, Schott AF, Crew KD, Lew DL, Fisch MJ, Moinpour CM, Wade JL, Hershman DL. Association between body mass index (BMI) and response to duloxetine for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-11-04.
Collapse
Affiliation(s)
- NL Henry
- University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Michigan, Ann Arbor, MI; AIM Specialty Health, Chicago, IL; Columbia University, New York, NY; Heartland NCORP, Decatur, IL
| | - JM Unger
- University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Michigan, Ann Arbor, MI; AIM Specialty Health, Chicago, IL; Columbia University, New York, NY; Heartland NCORP, Decatur, IL
| | - C Till
- University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Michigan, Ann Arbor, MI; AIM Specialty Health, Chicago, IL; Columbia University, New York, NY; Heartland NCORP, Decatur, IL
| | - AF Schott
- University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Michigan, Ann Arbor, MI; AIM Specialty Health, Chicago, IL; Columbia University, New York, NY; Heartland NCORP, Decatur, IL
| | - KD Crew
- University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Michigan, Ann Arbor, MI; AIM Specialty Health, Chicago, IL; Columbia University, New York, NY; Heartland NCORP, Decatur, IL
| | - DL Lew
- University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Michigan, Ann Arbor, MI; AIM Specialty Health, Chicago, IL; Columbia University, New York, NY; Heartland NCORP, Decatur, IL
| | - MJ Fisch
- University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Michigan, Ann Arbor, MI; AIM Specialty Health, Chicago, IL; Columbia University, New York, NY; Heartland NCORP, Decatur, IL
| | - CM Moinpour
- University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Michigan, Ann Arbor, MI; AIM Specialty Health, Chicago, IL; Columbia University, New York, NY; Heartland NCORP, Decatur, IL
| | - JL Wade
- University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Michigan, Ann Arbor, MI; AIM Specialty Health, Chicago, IL; Columbia University, New York, NY; Heartland NCORP, Decatur, IL
| | - DL Hershman
- University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Michigan, Ann Arbor, MI; AIM Specialty Health, Chicago, IL; Columbia University, New York, NY; Heartland NCORP, Decatur, IL
| |
Collapse
|
9
|
Hershman DL, Accordino M, Shen S, Buono D, Crew KD, Kalinsky K, Trivedi MS, Unger JM, Wright JD. Abstract PD6-10: Association between adherence to cardiovascular medications and cardiovascular events following a diagnosis of early stage breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd6-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Studies show that patients diagnosed with early-stage breast cancer (BC) are more likely to die from cardiovascular disease (CVD) than BC. Adherence to CVD medications, such as statins and antihypertensives, is poor in BC survivors, particularly in the year following diagnosis. The impact of non-adherence to CVD medications on cardiovascular events in BC survivors is unknown.
Methods: Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked dataset, we evaluated patients with non-metastatic BC who were diagnosed between 2006-2014. Prescriptions were identified for the treatment of hypertension, hyperlipidemia and diabetes. The pre-cancer diagnosis study period for adherence was defined as 1 year prior to the diagnosis of cancer. The follow up adherence period was between years 1 and 2 following the diagnosis of cancer, so the BC treatment period was not included. Adherence was defined as a medication possession ratio of 380%. A CVD event was defined as an ischemic event or acute heart failure. Patients with a CVD event prior to diagnosis were excluded. Logistic regression was performed for each non-cancer condition to define factors associated with medication non-adherence. Cox regression was used to calculate the association between CVD medication adherence and time-to-subsequent cardiac events, adjusted for baseline factors. Cox regression was performed separately for each non-cancer condition.
Results: Among 23,080 women with BC in the cohort, 15,576 were adherent to at least one CVD medication prior to diagnosis, and of these, 2732 (17.5%) were non-adherent to at least one medication following treatment. Among the women adherent to medications prior to diagnosis, 19.2% were non-adherent to hypertension medications, 26.2% were non-adherent to cholesterol medications, and 30.6% were non-adherent to diabetes medications following the first year of BC treatment. Factors that were associated with non-adherence to anti-hypertensives included receipt of chemotherapy (OR 1.24, p<0.001), other comorbidities (OR 1.34, p<0.001), higher stage (OR 1.18, p <0.001) and hormone receptor negative tumors (OR 1.15, p<0.001). Similar factors were associated with non-adherence to cholesterol medications, whereas only stage and tumor type were associated with non-adherence to diabetes medications. Non-adherence to hypertension medications compared to adherence following diagnosis was associated with an increased risk of having a CVD event (HR 1.33, 95% CI 1.18-1.51, p<0.001; 5-year cumulative incidence of 32% vs 26%, respectively, p<0.001). Similar results were seen for adherence to cholesterol medications (HR 1.21, 95% CI 1.05-1.40, p=0.009) and diabetes medications (HR 1.31, 95% CI 1.09-1.56, p=0.003).
Conclusions:In summary, we found that a large proportion of women who were previously adherent to their medications to prevent CVD events prior to their breast cancer diagnosis were non-adherent following treatment. Of concern, non-adherence to any of these classes of medications resulted in an increased risk of having a cardiovascular event. Improving outcomes and reducing morbidity following a breast cancer diagnosis also requires focused attention on non-breast cancer conditions.
Citation Format: Hershman DL, Accordino M, Shen S, Buono D, Crew KD, Kalinsky K, Trivedi MS, Unger JM, Wright JD. Association between adherence to cardiovascular medications and cardiovascular events following a diagnosis of early stage breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD6-10.
Collapse
Affiliation(s)
- DL Hershman
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - M Accordino
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - S Shen
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - D Buono
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - KD Crew
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - K Kalinsky
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - MS Trivedi
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - JM Unger
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - JD Wright
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA
| |
Collapse
|
10
|
Kalinsky K, Sparano JA, Zhong X, Andreopoulou E, Taback B, Wiechmann L, Feldman SM, Ananthakrishnan P, Ahmad A, Cremers S, Sireci AN, Cross JR, Marks DK, Mundi P, Connolly E, Crew KD, Maurer MA, Hibshoosh H, Lee S, Hershman DL. Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial. Clin Transl Oncol 2018; 20:1474-1483. [PMID: 29736694 DOI: 10.1007/s12094-018-1888-2] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2018] [Accepted: 04/26/2018] [Indexed: 12/19/2022]
Abstract
INTRODUCTION The PI3K/AKT/mTOR pathway is an oncogenic driver in breast cancer (BC). In this multi-center, pre-surgical study, we evaluated the tissue effects of the AKT inhibitor MK-2206 in women with stage I-III BC. MATERIALS AND METHODS Two doses of weekly oral MK2206 were administered at days - 9 and - 2 before surgery. The primary endpoint was reduction of pAktSer473 in breast tumor tissue from diagnostic biopsy to surgery. Secondary endpoints included changes in PI3K/AKT pathway tumor markers, tumor proliferation (ki-67), insulin growth factor pathway blood markers, pharmacokinetics (PK), genomics, and MK-2206 tolerability. Paired t tests were used to compare biomarker changes in pre- and post-MK-2206, and two-sample t tests to compare with prospectively accrued untreated controls. RESULTS Despite dose reductions, the trial was discontinued after 12 patients due to grade III rash, mucositis, and pruritus. While there was a trend to reduction in pAKT after MK-2206 (p = 0.06), there was no significant change compared to controls (n = 5, p = 0.65). After MK-2206, no significant changes in ki-67, pS6, PTEN, or stathmin were observed. There was no significant association between dose level and PK (p = 0.11). Compared to controls, MK-2206 significantly increased serum glucose (p = 0.02), insulin (p < 0.01), C-peptide (p < 0.01), and a trend in IGFBP-3 (p = 0.06). CONCLUSION While a trend to pAKT reduction after MK-2206 was observed, there was no significant change compared to controls. However, the accrued population was limited, due to toxicity being greater than expected. Pre-surgical trials can identify in vivo activity in the early drug development, but side effects must be considered in this healthy population.
Collapse
Affiliation(s)
- K Kalinsky
- Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, USA. .,Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Herbert Irving Pavilion, 161 Fort Washington Avenue, 10th Floor, Room 1069, New York, NY, 10032, USA.
| | - J A Sparano
- Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, New York, USA
| | - X Zhong
- Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, USA
| | | | - B Taback
- Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Herbert Irving Pavilion, 161 Fort Washington Avenue, 10th Floor, Room 1069, New York, NY, 10032, USA.,Department of Surgery, College of Physicians and Surgeons, Columbia University, New York, USA
| | - L Wiechmann
- Department of Surgery, College of Physicians and Surgeons, Columbia University, New York, USA
| | - S M Feldman
- Department of Surgery, Albert Einstein College of Medicine, Montefiore Medical Center, New York, USA
| | | | - A Ahmad
- Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, USA
| | - S Cremers
- Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, USA
| | - A N Sireci
- Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, USA
| | - J R Cross
- Donald B. and Catherine C. Marron Cancer Metabolism Center, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - D K Marks
- Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, USA
| | - P Mundi
- Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, USA.,Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Herbert Irving Pavilion, 161 Fort Washington Avenue, 10th Floor, Room 1069, New York, NY, 10032, USA
| | - E Connolly
- Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Herbert Irving Pavilion, 161 Fort Washington Avenue, 10th Floor, Room 1069, New York, NY, 10032, USA.,Department of Radiation Oncology, College of Physicians and Surgeons, Columbia University, New York, USA
| | - K D Crew
- Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, USA.,Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Herbert Irving Pavilion, 161 Fort Washington Avenue, 10th Floor, Room 1069, New York, NY, 10032, USA.,Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, USA
| | - M A Maurer
- Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, USA.,Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Herbert Irving Pavilion, 161 Fort Washington Avenue, 10th Floor, Room 1069, New York, NY, 10032, USA
| | - H Hibshoosh
- Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Herbert Irving Pavilion, 161 Fort Washington Avenue, 10th Floor, Room 1069, New York, NY, 10032, USA.,Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, USA
| | - S Lee
- Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Herbert Irving Pavilion, 161 Fort Washington Avenue, 10th Floor, Room 1069, New York, NY, 10032, USA.,Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, USA
| | - D L Hershman
- Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, USA.,Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Herbert Irving Pavilion, 161 Fort Washington Avenue, 10th Floor, Room 1069, New York, NY, 10032, USA.,Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, USA
| |
Collapse
|
11
|
Yuan A, Topkara V, Hershman DL, Kalinsky K, Accordino MK, Trivedi MS, Yu A, Genkinger JM, Crew KD. Abstract P6-12-17: Identifying risk factors and effect modifiers of trastuzumab-induced cardiotoxicity among multi-ethnic women with early-stage HER2-positive breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-12-17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Trastuzumab-based adjuvant therapy is the current standard of care for early-stage HER2-positive breast cancer. However, trastuzumab has also been associated with an increased risk of cardiotoxicity, especially when given following an anthracycline. Trastuzumab-induced cardiotoxicity (TIC) can present as asymptomatic left ventricular ejection fraction (LVEF) decline or symptomatic heart failure. Our objective was to identify predictors of TIC among multi-ethnic patients with early-stage HER2-positive breast cancer. Unlike prior observational studies, our study included a high representation of racial/ethnic minorities, who are at increased risk of cardiovascular disease (CVD) compared to non-Hispanic whites.
Methods: We conducted a retrospective cohort study in patients with stage I-III HER2-positive breast cancer, diagnosed from 2007 to 2015 at Columbia University Medical Center (CUMC) in New York, NY, who had received adjuvant trastuzumab therapy. Participants had at least two serial echocardiograms or MUGA scans to assess TIC, which was defined as at least a 10% decrease in LVEF from baseline or LVEF <50%. LVEF recovery was defined as at least a 10% increase in LVEF or LVEF >50%. We conducted descriptive statistics and univariate and multivariable logistic regression to estimate the associations between socio-demographic factors, breast tumor and treatment characteristics, and CVD risk factors (including smoking status, body mass index [BMI], hypertension, diabetes, hyperlipidemia, coronary artery disease) and TIC. Interactions between race/ethnicity and CVD risk factors were assessed using a logistic regression model.
Results: In our study population (N=279), the mean age was 52.7 years (standard deviation, 12.1) with 36.6% non-Hispanic white, 18.3% non-Hispanic black, 34.8% Hispanic, and 10.4% Asian patients. There were no differences by race/ethnicity in tumor and treatment characteristics (over half had prior anthracyclines), but racial/ethnic minorities had higher BMI and were more likely to have hypertension compared to non-Hispanic whites. About a third of patients developed TIC and 14.7% had an LVEF decline to <50%, of which 15 (16.1%) experienced LVEF recovery. In multivariable analysis, prior anthracycline use and hypertension were significantly associated with increased odds of developing TIC (odds ratio [OR]: 2.25, 95% confidence interval [CI]: 1.25, 4.06; OR: 2.13, 95% CI: 1.15, 3.93, respectively). There was a significant interaction (p=0.027) between race/ethnicity and hypertension on odds of developing TIC with hypertensive non-Hispanic white patients experiencing 6.05 (95% CI: 2.19, 16.75) times the odds of developing TIC compared to non-hypertensive non-Hispanic whites.
Discussion: We observed a higher incidence of TIC and lower incidence of LVEF recovery compared to previous clinical trials. Given patient selection for clinical trials, our results may be more representative of clinical practice settings. We found a particularly high risk among non-Hispanic white patients with hypertension. Patients with hypertension may require closer blood pressure monitoring and treatment with anti-hypertensives in order to reduce risk of developing cardiotoxicity.
Citation Format: Yuan A, Topkara V, Hershman DL, Kalinsky K, Accordino MK, Trivedi MS, Yu A, Genkinger JM, Crew KD. Identifying risk factors and effect modifiers of trastuzumab-induced cardiotoxicity among multi-ethnic women with early-stage HER2-positive breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-12-17.
Collapse
Affiliation(s)
- A Yuan
- Columbia University Medical Center, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
| | - V Topkara
- Columbia University Medical Center, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
| | - DL Hershman
- Columbia University Medical Center, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
| | - K Kalinsky
- Columbia University Medical Center, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
| | - MK Accordino
- Columbia University Medical Center, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
| | - MS Trivedi
- Columbia University Medical Center, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
| | - A Yu
- Columbia University Medical Center, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
| | - JM Genkinger
- Columbia University Medical Center, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
| | - KD Crew
- Columbia University Medical Center, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
| |
Collapse
|
12
|
Onishi M, Connolly EP, Wright JD, Vasan S, Gross T, Tsai WY, Chen L, Neugut AI, Accordino MK, Kalinsky K, Crew KD, Hershman DL. Abstract PD7-03: Cost-effectiveness analysis of intraoperative radiotherapy for ductal carcinoma in situ. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd7-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Whole breast radiation therapy (WBRT) following lumpectomy for ductal carcinoma in situ (DCIS) is standard of care, however, the risk of local recurrence with and without radiation ranges as low as 0.9% vs. 6.7% over 7 years. Intraoperative radiotherapy (IORT) is a potential alternative with advantages of decreased toxicity to adjacent organs, convenience, and improved quality of life. While prospective trials of IORT for DCIS are ongoing, the objective of this study was to estimate the cost-effectiveness of IORT vs. WBRT vs. no radiation for DCIS.
Methods
We developed a Markov model using TreeAge Pro 2016 to evaluate the cost-effectiveness of WBRT, IORT, and no radiation in patients with DCIS following lumpectomy. Health states included disease free, local recurrence (ipsilateral DCIS or invasive cancer), distant recurrence or death due to breast cancer, and death due to non-breast cancer causes. A 10-year time horizon and societal perspective were used. Model input parameters were derived from the literature. Costs reflected 2016 Medicare rates. The primary endpoint was incremental cost-effectiveness ratio (ICER), defined as the difference in cost, divided by the difference in quality-adjusted life years (QALYs) of two interventions. We performed analyses of subgroups defined according to DCIS risk (histologic grade, Oncotype Dx® DCIS recurrence score, low risk per RTOG 9804 criteria) and endocrine therapy use (none, tamoxifen, aromatase inhibitor). Sensitivity analyses explored uncertainty in the model.
Results
IORT was the most cost-effective strategy, with an increase of 0.18 QALYs at an incremental cost of $4,728, corresponding to an ICER of $26,943/QALY when compared with no radiation therapy. WBRT resulted in an increase in 0.18 QALYs at an incremental cost of $6859, corresponding to an ICER of $39,085/QALY. For both strategies, the ICERs did not exceed the willingness to pay (WTP) threshold of $100,000.
IORT remained the most cost-effective strategy across DCIS risk groups, but was more cost-effective in higher risk patients, as demonstrated by lower ICERs. In low risk DCIS defined by RTOG 9804 criteria, no radiation was most cost-effective. The ICERs for IORT and WBRT, $152,753 and $208,204/QALY, respectively, exceeded the WTP threshold. IORT remained cost-effective in the setting of endocrine therapy use.
Incremental Cost-Effectiveness Ratios (ICER) for each radiation strategy for the base case and scenario analyses ICER ($/QALY) No RTIORTWBRTBase Case Analysis 26,94339,085 Scenario Analysis by DCIS Risk GroupHistologic Grade - Low 36,81152,219- High 25,64337,137 Oncotype Dx DCIS Score - Low 92,892126,398- High 32,00345,690 Low Risk DCIS 152,753208,204 Scenario Analysis by Endocrine TherapyNo Tamoxifen 23,38734,373Tamoxifen 47,81166,616 Tamoxifen 31,96146,272Aromatase Inhibitor 41,31658,674
Conclusion
IORT was the most cost-effective radiation strategy for DCIS compared to WBRT and no radiation. This applied to all subgroups with the exception of low-risk DCIS defined by RTOG 9804 criteria for whom no radiation was the most cost-effective strategy. These findings provide support for ongoing studies examining the role of IORT for DCIS with high-risk features, as well as alternative treatment strategies for low-risk DCIS.
Citation Format: Onishi M, Connolly EP, Wright JD, Vasan S, Gross T, Tsai W-Y, Chen L, Neugut AI, Accordino MK, Kalinsky K, Crew KD, Hershman DL. Cost-effectiveness analysis of intraoperative radiotherapy for ductal carcinoma in situ [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD7-03.
Collapse
Affiliation(s)
- M Onishi
- Columbia University Medical Center, New York, NY
| | - EP Connolly
- Columbia University Medical Center, New York, NY
| | - JD Wright
- Columbia University Medical Center, New York, NY
| | - S Vasan
- Columbia University Medical Center, New York, NY
| | - T Gross
- Columbia University Medical Center, New York, NY
| | - W-Y Tsai
- Columbia University Medical Center, New York, NY
| | - L Chen
- Columbia University Medical Center, New York, NY
| | - AI Neugut
- Columbia University Medical Center, New York, NY
| | - MK Accordino
- Columbia University Medical Center, New York, NY
| | - K Kalinsky
- Columbia University Medical Center, New York, NY
| | - KD Crew
- Columbia University Medical Center, New York, NY
| | - DL Hershman
- Columbia University Medical Center, New York, NY
| |
Collapse
|
13
|
Trivedi MS, Colbeth H, Yi H, Vanegas A, Starck R, Chung WK, Appelbaum PS, Kukafka R, Schechter I, Crew KD. Abstract P4-06-19: Understanding factors associated with uptake of BRCA genetic testing among Orthodox Jewish women using a mixed-methods approach. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p4-06-19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The prevalence of BRCA1/2 mutations among Ashkenazi Jews is 1 in 40. Compared to family history-based BRCA testing, population-based testing has been shown to detect more mutation carriers in this population. Orthodox Jews (OJ) are the largest and fastest-growing Jewish population in NY and represent a spectrum of observance including Modern Orthodox, Yeshivish, and Chassidic. This understudied population has unique social, cultural, and religious factors that may influence BRCA genetic testing. We examined factors influencing BRCA genetic testing decision-making and uptake among OJ women.
Methods: Using a mixed-methods approach, we conducted a cross-sectional online survey and 4 focus groups among OJ women in 5 communities in the NY/NJ area. The online survey included items on demographics, breast cancer risk factors, and validated measures of genetic testing intention/knowledge, breast cancer worry/risk perception, stigma, and religious/cultural factors affecting medical decision-making. Descriptive statistics and bivariate and multivariable logistic regression models were conducted. We conducted 4 focus groups with purposive sampling of women who responded to the survey. The qualitative analysis of the semi-structured focus group discussions further explored factors affecting BRCA genetic testing uptake.
Results: Among 321 evaluable survey participants, median age was 47 years (range, 25-82); 55.8% were Modern Orthodox, 30.5% Yeshivish, and 2.8% Chassidic; 84% were married; 6.2% and 0.6% had a history of breast and ovarian cancer, respectively. Although 57.6% had a masters or doctoral degree, only 37.7% had adequate genetic testing knowledge. Nearly 20% of the surveyed women had undergone BRCA genetic testing. After adjusting for known confounders, women who met family history criteria for BRCA genetic testing were nearly 10 times more likely to undergo genetic testing. Modern Orthodox compared to non-Modern Orthodox women and married compared to unmarried women were more likely to undergo genetic testing (odds ratio [OR]=2.31, 95% confidence interval [CI]=1.03-5.17; OR=3.49, 95% CI=1.03-11.80, respectively). Compared to Modern Orthodox women, non-Modern Orthodox women were more likely to consult with a rabbi or religious figure when considering genetic testing and other medical decisions. The focus group participants (N=31) confirmed the importance of rabbinic consultation in medical decision-making. Although stigma was not associated with genetic testing uptake in our survey data, it emerged as a prominent factor in decision-making among focus group participants due to its potential impact on marriageability and family.
Conclusions: We found that non-Modern Orthodox and unmarried women are less likely to seek BRCA genetic testing. Among non-Modern Orthodox women, rabbinic consultation was an important factor in genetic testing decision-making. By understanding the religious and cultural issues regarding genetic testing in the OJ community and by engaging faith-based leaders, we can develop culturally sensitive interventions designed to enhance knowledge and informed choice about BRCA genetic testing, which may facilitate the implementation of population-based genetic screening among Ashkenazi Jews.
Citation Format: Trivedi MS, Colbeth H, Yi H, Vanegas A, Starck R, Chung WK, Appelbaum PS, Kukafka R, Schechter I, Crew KD. Understanding factors associated with uptake of BRCA genetic testing among Orthodox Jewish women using a mixed-methods approach [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-06-19.
Collapse
Affiliation(s)
- MS Trivedi
- College of Physicians and Surgeons, Columbia University, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; Mailman School of Public Health, Columbia University, New York, NY; Teachers College, Columbia University, New York, NY; Institute for Applied Research and Community Collaboration (ARCC), Spring Valley, NY
| | - H Colbeth
- College of Physicians and Surgeons, Columbia University, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; Mailman School of Public Health, Columbia University, New York, NY; Teachers College, Columbia University, New York, NY; Institute for Applied Research and Community Collaboration (ARCC), Spring Valley, NY
| | - H Yi
- College of Physicians and Surgeons, Columbia University, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; Mailman School of Public Health, Columbia University, New York, NY; Teachers College, Columbia University, New York, NY; Institute for Applied Research and Community Collaboration (ARCC), Spring Valley, NY
| | - A Vanegas
- College of Physicians and Surgeons, Columbia University, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; Mailman School of Public Health, Columbia University, New York, NY; Teachers College, Columbia University, New York, NY; Institute for Applied Research and Community Collaboration (ARCC), Spring Valley, NY
| | - R Starck
- College of Physicians and Surgeons, Columbia University, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; Mailman School of Public Health, Columbia University, New York, NY; Teachers College, Columbia University, New York, NY; Institute for Applied Research and Community Collaboration (ARCC), Spring Valley, NY
| | - WK Chung
- College of Physicians and Surgeons, Columbia University, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; Mailman School of Public Health, Columbia University, New York, NY; Teachers College, Columbia University, New York, NY; Institute for Applied Research and Community Collaboration (ARCC), Spring Valley, NY
| | - PS Appelbaum
- College of Physicians and Surgeons, Columbia University, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; Mailman School of Public Health, Columbia University, New York, NY; Teachers College, Columbia University, New York, NY; Institute for Applied Research and Community Collaboration (ARCC), Spring Valley, NY
| | - R Kukafka
- College of Physicians and Surgeons, Columbia University, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; Mailman School of Public Health, Columbia University, New York, NY; Teachers College, Columbia University, New York, NY; Institute for Applied Research and Community Collaboration (ARCC), Spring Valley, NY
| | - I Schechter
- College of Physicians and Surgeons, Columbia University, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; Mailman School of Public Health, Columbia University, New York, NY; Teachers College, Columbia University, New York, NY; Institute for Applied Research and Community Collaboration (ARCC), Spring Valley, NY
| | - KD Crew
- College of Physicians and Surgeons, Columbia University, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; Mailman School of Public Health, Columbia University, New York, NY; Teachers College, Columbia University, New York, NY; Institute for Applied Research and Community Collaboration (ARCC), Spring Valley, NY
| |
Collapse
|
14
|
Vanegas A, Vargas JM, Kukafka R, Crew KD. Abstract OT3-01-02: Randomized controlled trial of web-based decision support tools for high-risk women and primary care providers to increase breast cancer chemoprevention. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot3-01-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast cancer chemoprevention with selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) is under-utilized despite several randomized controlled trials demonstrating a 40-65% decrease in breast cancer incidence among high-risk women. Reasons for low chemoprevention uptake include inadequate time for counseling, insufficient knowledge about SERMs and AIs, and concerns about side effects. Intervention trials of clinical decision support tools designed to increase chemoprevention uptake have been met with limited success. We have developed web-based decision aids (DAs), RealRisks for high-risk women and BNAV for primary care providers (PCPs). Our intervention differs from the prior literature in that we are targeting both patients and PCPs with personalized risk reports and education about the risks and benefits of chemoprevention. Our patient-centered decision aid is available in English and Spanish and has been rigorously tested in multi-ethnic women with varying health literacy. We hypothesize that standard educational materials combined with RealRisks and BNAV will increase uptake of SERMs or AIs among high-risk women in the primary care setting.
Trial Design: We are conducting a randomized controlled trial at Columbia University Medical Center (CUMC) in New York, NY, consisting of standard educational materials combined with RealRisks and BNAV or standard educational materials alone among 300 high-risk women stratified by Hispanic ethnicity and menopausal status. Women in the intervention arm are given access to the RealRisks DA, and, based on their responses, an action plan is generated summarizing their breast cancer risk profile, risks/benefits of SERMs and AIs, and personal preferences for chemoprevention. PCPs are given their patient's tailored risk report, which is the providers' view of the action plan, and are invited to access the BNAV tool.
Eligibility Criteria: 1) Women, aged 35-75 years; 2) 5-year invasive breast cancer risk ≥1.67% or lifetime risk ≥20% according to the Gail model (Breast Cancer Risk Assessment Tool) or history of lobular carcinoma in situ; 3) No prior use of SERM or AI; 4) No prior history of breast cancer; 5) PCP at CUMC; 6) English- or Spanish-speaking.
Specific Aims: The primary endpoint is chemoprevention uptake of a SERM or AI at 6 months based upon documentation in the electronic health record. Secondarily, we use validated surveys to assess breast cancer and chemoprevention knowledge, accuracy of perceived breast cancer risk and worry, decision self-efficacy, and informed choice at baseline, 1 month, 6 months, and post-clinical encounter with the patients' PCP. PCPs will complete a 1-time survey on personal and professional characteristics and practice patterns.
Statistical Methods: With a total sample size of 300 (150 per arm), assuming a Type 1 error of 5% and a 10% drop-out rate (effective sample size of 270), we will have >80% power to detect a difference in chemoprevention uptake of 1% in the control arm and 10% in the active intervention arm.
Target Accrual: 300. Seventy-eight participants accrued as of June 2017. Accrual completion expected November 2018.
Contact: Katherine Crew, CUMC, kd59@cumc.columbia.edu
Citation Format: Vanegas A, Vargas JM, Kukafka R, Crew KD. Randomized controlled trial of web-based decision support tools for high-risk women and primary care providers to increase breast cancer chemoprevention [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT3-01-02.
Collapse
Affiliation(s)
- A Vanegas
- Columbia University Medical Center, New York, NY
| | - JM Vargas
- Columbia University Medical Center, New York, NY
| | - R Kukafka
- Columbia University Medical Center, New York, NY
| | - KD Crew
- Columbia University Medical Center, New York, NY
| |
Collapse
|
15
|
Crew KD, Anderson G, Hershman DL, Terry MB, Tehranifar P, Lew DL, Yee M, Brown EA, Kairouz SS, Minasian LM, Ford L, Neuhouser ML, Arun BK, Brown PH. Abstract P5-15-02: Withdrawn. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-15-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- KD Crew
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| | - G Anderson
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| | - DL Hershman
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| | - MB Terry
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| | - P Tehranifar
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| | - DL Lew
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| | - M Yee
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| | - EA Brown
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| | - SS Kairouz
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| | - LM Minasian
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| | - L Ford
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| | - ML Neuhouser
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| | - BK Arun
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| | - PH Brown
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
16
|
Hershman DL, Unger JM, Greenlee H, Capodice J, Lew DL, Kengla AT, Melnik MK, Jorgensen CW, Kreisle WH, Minasian LM, Fisch MJ, Henry L, Crew KD. Abstract GS4-04: Randomized blinded sham- and waitlist-controlled trial of acupuncture for joint symptoms related to aromatase inhibitors in women with early stage breast cancer (S1200). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-gs4-04] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Musculoskeletal symptoms are the most common side effect of aromatase inhibitors (AIs) and can result in decreased quality of life and discontinuation of therapy. Pilot data from two prior single institution studies showed that acupuncture decreased AI-induced joint symptoms in breast cancer (BC) patients.
Methods: We conducted a SWOG multicenter randomized controlled trial among postmenopausal women with early stage BC. Patients taking an AI for ≥30 days and having a worst pain score of ≥3 out of 10 using the Brief Pain Inventory (BPI-WP) were eligible. Subjects were randomized at a 2:1:1 ratio to true acupuncture (TA) vs. sham acupuncture (SA) vs. waitlist control (WC). The TA protocol used a standardized protocol of body and auricular acupoints tailored to joint symptoms. The similarly standardized SA protocol utilized superficial needling of non-acupoints. Both the TA and SA protocols consisted of a 12 week intervention, with 12 sessions administered over 6 weeks, followed by 1 session per week for 6 additional weeks. The primary endpoint was change in the BPI-WP (worst pain) score at 6 weeks. Secondary outcomes included other BPI scores, the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) for the hips and knees, the Modified Score for the Assessment of Chronic Rheumatoid Affections of the Hands (M-SACRAH), and functional testing with grip strength and "Timed Get Up and Go" (TGUG). The design specified alpha=.025 two-sided tests to account for two independent comparisons (TA vs. SA and TA vs. WC).
Results: Among 226 patients registered, 110 were randomized to TA, 59 to SA and 57 to WC. Baseline characteristics were similar between the groups. In a linear regression adjusting for the baseline score and stratification factors, 6-week mean BPI-WP scores were 0.92 points lower (correlating with less pain) in the TA compared to SA arm (95% CI: 0.20-1.65, p=.01), and were 0.96 points lower in the TA compared to WC arm (95% CI: 0.24-1.67, p=.01). The proportion of patients experiencing a clinically meaningful (>2) reduction (i.e. improvement) in BPI-WP was 58% for TA compared to 33% on SA and 31% on WC. Patients randomized to TA had improved symptoms compared to SA at week 6 according to all other BPI pain measures (average pain, p=.04; pain interference, p=.02; pain severity, p=.05; worst stiffness, p=.02). Results were similar compared to WC. Patients randomized to TA compared to SA or WC had statistically significant or marginally statistically significant improvements in BPI pain measures at week 12. Patients randomized to TA had generally improved symptoms compared to SA or WC at week 6 and at week 12 according to the M-SACRAH and WOMAC measures (p<0.05). With regard to adverse events, more patients on the TA arm experienced Grade 1 bruising compared to SA (47% vs. 25%, p=.01). No other differences by arm for selected adverse events were observed.
Conclusions: This study was the first large multicenter trial to investigate the effect of acupuncture in treating AI-induced joint symptoms in BC patients. According to multiple measures, TA generated better outcomes than either SA or WC with minimal toxicity.
Citation Format: Hershman DL, Unger JM, Greenlee H, Capodice J, Lew DL, Kengla AT, Melnik MK, Jorgensen CW, Kreisle WH, Minasian LM, Fisch MJ, Henry L, Crew KD. Randomized blinded sham- and waitlist-controlled trial of acupuncture for joint symptoms related to aromatase inhibitors in women with early stage breast cancer (S1200) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr GS4-04.
Collapse
Affiliation(s)
- DL Hershman
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; Mount Sinai Hospital, New York, NY; Kaiser Permanente Medical Center, Walnut Creek, CA; Spectrum Health Medical Group, Grand Rapids, MI; NCORP of the Carolinas (Greenville Health System), Greenville, SC; St. Luke's Mountain States Tumor Institute, Boise, ID; National Cancer Institute, Bethesda, MD; AIM Specialty Health, Chicago, IL; University of Utah Huntsman Cancer Institute, Salt Lake City, UT
| | - JM Unger
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; Mount Sinai Hospital, New York, NY; Kaiser Permanente Medical Center, Walnut Creek, CA; Spectrum Health Medical Group, Grand Rapids, MI; NCORP of the Carolinas (Greenville Health System), Greenville, SC; St. Luke's Mountain States Tumor Institute, Boise, ID; National Cancer Institute, Bethesda, MD; AIM Specialty Health, Chicago, IL; University of Utah Huntsman Cancer Institute, Salt Lake City, UT
| | - H Greenlee
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; Mount Sinai Hospital, New York, NY; Kaiser Permanente Medical Center, Walnut Creek, CA; Spectrum Health Medical Group, Grand Rapids, MI; NCORP of the Carolinas (Greenville Health System), Greenville, SC; St. Luke's Mountain States Tumor Institute, Boise, ID; National Cancer Institute, Bethesda, MD; AIM Specialty Health, Chicago, IL; University of Utah Huntsman Cancer Institute, Salt Lake City, UT
| | - J Capodice
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; Mount Sinai Hospital, New York, NY; Kaiser Permanente Medical Center, Walnut Creek, CA; Spectrum Health Medical Group, Grand Rapids, MI; NCORP of the Carolinas (Greenville Health System), Greenville, SC; St. Luke's Mountain States Tumor Institute, Boise, ID; National Cancer Institute, Bethesda, MD; AIM Specialty Health, Chicago, IL; University of Utah Huntsman Cancer Institute, Salt Lake City, UT
| | - DL Lew
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; Mount Sinai Hospital, New York, NY; Kaiser Permanente Medical Center, Walnut Creek, CA; Spectrum Health Medical Group, Grand Rapids, MI; NCORP of the Carolinas (Greenville Health System), Greenville, SC; St. Luke's Mountain States Tumor Institute, Boise, ID; National Cancer Institute, Bethesda, MD; AIM Specialty Health, Chicago, IL; University of Utah Huntsman Cancer Institute, Salt Lake City, UT
| | - AT Kengla
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; Mount Sinai Hospital, New York, NY; Kaiser Permanente Medical Center, Walnut Creek, CA; Spectrum Health Medical Group, Grand Rapids, MI; NCORP of the Carolinas (Greenville Health System), Greenville, SC; St. Luke's Mountain States Tumor Institute, Boise, ID; National Cancer Institute, Bethesda, MD; AIM Specialty Health, Chicago, IL; University of Utah Huntsman Cancer Institute, Salt Lake City, UT
| | - MK Melnik
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; Mount Sinai Hospital, New York, NY; Kaiser Permanente Medical Center, Walnut Creek, CA; Spectrum Health Medical Group, Grand Rapids, MI; NCORP of the Carolinas (Greenville Health System), Greenville, SC; St. Luke's Mountain States Tumor Institute, Boise, ID; National Cancer Institute, Bethesda, MD; AIM Specialty Health, Chicago, IL; University of Utah Huntsman Cancer Institute, Salt Lake City, UT
| | - CW Jorgensen
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; Mount Sinai Hospital, New York, NY; Kaiser Permanente Medical Center, Walnut Creek, CA; Spectrum Health Medical Group, Grand Rapids, MI; NCORP of the Carolinas (Greenville Health System), Greenville, SC; St. Luke's Mountain States Tumor Institute, Boise, ID; National Cancer Institute, Bethesda, MD; AIM Specialty Health, Chicago, IL; University of Utah Huntsman Cancer Institute, Salt Lake City, UT
| | - WH Kreisle
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; Mount Sinai Hospital, New York, NY; Kaiser Permanente Medical Center, Walnut Creek, CA; Spectrum Health Medical Group, Grand Rapids, MI; NCORP of the Carolinas (Greenville Health System), Greenville, SC; St. Luke's Mountain States Tumor Institute, Boise, ID; National Cancer Institute, Bethesda, MD; AIM Specialty Health, Chicago, IL; University of Utah Huntsman Cancer Institute, Salt Lake City, UT
| | - LM Minasian
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; Mount Sinai Hospital, New York, NY; Kaiser Permanente Medical Center, Walnut Creek, CA; Spectrum Health Medical Group, Grand Rapids, MI; NCORP of the Carolinas (Greenville Health System), Greenville, SC; St. Luke's Mountain States Tumor Institute, Boise, ID; National Cancer Institute, Bethesda, MD; AIM Specialty Health, Chicago, IL; University of Utah Huntsman Cancer Institute, Salt Lake City, UT
| | - MJ Fisch
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; Mount Sinai Hospital, New York, NY; Kaiser Permanente Medical Center, Walnut Creek, CA; Spectrum Health Medical Group, Grand Rapids, MI; NCORP of the Carolinas (Greenville Health System), Greenville, SC; St. Luke's Mountain States Tumor Institute, Boise, ID; National Cancer Institute, Bethesda, MD; AIM Specialty Health, Chicago, IL; University of Utah Huntsman Cancer Institute, Salt Lake City, UT
| | - L Henry
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; Mount Sinai Hospital, New York, NY; Kaiser Permanente Medical Center, Walnut Creek, CA; Spectrum Health Medical Group, Grand Rapids, MI; NCORP of the Carolinas (Greenville Health System), Greenville, SC; St. Luke's Mountain States Tumor Institute, Boise, ID; National Cancer Institute, Bethesda, MD; AIM Specialty Health, Chicago, IL; University of Utah Huntsman Cancer Institute, Salt Lake City, UT
| | - KD Crew
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; Mount Sinai Hospital, New York, NY; Kaiser Permanente Medical Center, Walnut Creek, CA; Spectrum Health Medical Group, Grand Rapids, MI; NCORP of the Carolinas (Greenville Health System), Greenville, SC; St. Luke's Mountain States Tumor Institute, Boise, ID; National Cancer Institute, Bethesda, MD; AIM Specialty Health, Chicago, IL; University of Utah Huntsman Cancer Institute, Salt Lake City, UT
| |
Collapse
|
17
|
Yuan S, Manley HJ, Ha R, Yu A, Genkinger JM, Crew KD. Abstract PD2-15: Effect of mammography screening frequency on false-positive biopsy rates and detection of local recurrence among breast cancer survivors. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd2-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Current guidelines are for yearly mammograms in women with early-stage breast cancer. Among breast cancer survivors treated with lumpectomy, semi-annual compared to annual screening mammography of the ipsilateral breast has been associated with early detection of local recurrence. However, a potential harm of more frequent screening is false-positive breast biopsies that may lead to negative psychosocial effects and increased costs. Our objective was to investigate how frequency of screening mammograms affects rates of false-positive biopsy results and local recurrences among breast cancer survivors.
Methods: We conducted a retrospective cohort study at Columbia University Medical Center (CUMC) in New York, NY of women diagnosed with stage 0-III breast cancer between 2007 and 2015, who were treated with lumpectomy and had at least 2 screening mammograms at CUMC within the first 3 years after diagnosis. Demographic and clinical information, including tumor characteristics and breast cancer treatments, were collected from the electronic health record. Frequency of mammography screening was defined as the median interval between 2 consecutive mammograms (every 6 months vs. yearly). Both false-positive biopsy results and local recurrences were identified by review of breast pathology reports. A false-positive biopsy was defined as a diagnostic breast biopsy without evidence of invasive or non-invasive cancer. Descriptive statistics and logistic regression models were conducted to examine relationships between covariates and either false-positive biopsy or local recurrence.
Results: In our sample (n=1257), the median age at breast cancer diagnosis was 60 years (range, 24-93), including 47% non-Hispanic white, 14% non-Hispanic black, 31% Hispanic, and 7% Asian. Nearly 80% of women had semi-annual screening mammography of the ipsilateral breast during the first 3 years after breast cancer diagnosis. In univariate analysis, higher body mass index, more advanced stage disease, higher tumor grade, and receipt of chemotherapy, hormonal therapy, and radiation therapy were associated with more frequent screening. Comparing women who screened every 6 months vs. yearly, there was no difference in local recurrence rates (4.1% vs. 3.9%), including screen-detected or invasive/non-invasive breast cancer recurrences. In multivariable analysis, women who screened every 6 months compared to yearly had a greater than 2-fold increased risk of having a false-positive biopsy (OR: 2.40; 95% CI: 1.50-3.86). Also, younger age at diagnosis, higher tumor grade, and receipt of chemotherapy were associated with higher false positive rates, adjusting for covariates.
Conclusions: We observed that women with early-stage breast cancer treated with lumpectomy who underwent semi-annual vs. annual screening mammography had more false-positive breast biopsies, but no difference in local recurrence rates. To date, there is no evidence that more frequent screening in breast cancer patients is associated with improved survival. Future studies are needed to determine optimal screening strategies for breast cancer survivors, including frequency of screening and use of supplemental breast imaging with ultrasound, MRI, or tomosynthesis.
Citation Format: Yuan S, Manley HJ, Ha R, Yu A, Genkinger JM, Crew KD. Effect of mammography screening frequency on false-positive biopsy rates and detection of local recurrence among breast cancer survivors [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD2-15.
Collapse
Affiliation(s)
- S Yuan
- Columbia University Medical Center, New York, NY
| | - HJ Manley
- Columbia University Medical Center, New York, NY
| | - R Ha
- Columbia University Medical Center, New York, NY
| | - A Yu
- Columbia University Medical Center, New York, NY
| | - JM Genkinger
- Columbia University Medical Center, New York, NY
| | - KD Crew
- Columbia University Medical Center, New York, NY
| |
Collapse
|
18
|
Coe AM, Trivedi MS, Vanegas A, Kukafka R, Crew KD. Abstract P2-07-01: Chemoprevention uptake among women with atypical hyperplasia, lobular and ductal carcinoma in situ. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-07-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Chemoprevention with anti-estrogens can reduce breast cancer risk among high-risk women. However, uptake is estimated to be lower than 15% among women offered anti-estrogens. Women with atypical hyperplasia (AH), lobular carcinoma in situ (LCIS), and ductal carcinoma in situ (DCIS) are at an increased risk of developing invasive breast cancer and often derive more benefit from anti-estrogens compared to other high-risk populations. We sought to determine which factors are associated with chemoprevention uptake in a population of women with AH, LCIS, and DCIS.
Methods: We conducted a retrospective cohort study at an urban academic center in New York, NY of women diagnosed with AH/LCIS/DCIS between 2007 and 2015 without a history of invasive breast cancer (n=1719). Demographic and clinical information, including type of anti-estrogen and medical oncology referral, were collected from the electronic health record. Breast disease in each patient was classified according to the most advanced lesion (DCIS>LCIS>AH). A subset of women with AH/LCIS/DCIS scheduled for an initial consultation with a medical oncologist (n=73) completed questionnaires on their breast cancer and chemoprevention knowledge, risk perception, and behavioral intentions. Descriptive statistics were generated and univariate and multivariable log-binomial regression were used to estimate the association between sociodemographic and clinical factors and chemoprevention uptake.
Results: In our sample, mean age was 60 years (SD 12); white/black/Hispanic/Asian/other (%): 45/9/23/6/17; AH/LCIS/DCIS (%): 35/24/41; and 33% were referred to a medical oncologist. A total of 505 (29%) women had initiated an anti-estrogen, including 54% who used tamoxifen, 15% raloxifene, 19% aromatase inhibitors, and 11% who tried multiple anti-estrogens. Older women and Hispanics compared to non-Hispanic whites were more likely to take anti-estrogens. Compared to women with AH, LCIS (RR: 1.43; 95% CI: 1.16-1.76) and DCIS (RR: 1.54; 95% CI: 1.28-1.86) were significantly associated with chemoprevention uptake. Medical oncology referral was the strongest predictor of chemoprevention uptake (RR: 5.79; 95% CI: 4.80-6.98). According to the survey data, many women had heard of anti-estrogens for chemoprevention (75%), but few were knowledgeable about it. The majority of participants were worried about the side effects of chemoprevention (72%) and considered them very serious (57%). Satisfaction was high among those who reported making a decision to take chemoprevention, however, only 50% of survey participants thought the benefits of anti-estrogens were worth the risks.
Conclusions: At our center, women with AH, LCIS, and DCIS have higher rates of chemoprevention uptake compared to the reported literature. Despite the potential for younger women to see a greater lifelong benefit from chemoprevention, our results indicate this population may be less likely to use anti-estrogens. Misperceptions about personal breast cancer risk and chemoprevention adverse effects may be barriers to uptake. Improving patient-provider communication about breast cancer risk and the risks and benefits of chemoprevention may facilitate informed-decision making about anti-estrogen therapy.
Citation Format: Coe AM, Trivedi MS, Vanegas A, Kukafka R, Crew KD. Chemoprevention uptake among women with atypical hyperplasia, lobular and ductal carcinoma in situ [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-07-01.
Collapse
Affiliation(s)
- AM Coe
- Columbia University Medical Center, New York, NY
| | - MS Trivedi
- Columbia University Medical Center, New York, NY
| | - A Vanegas
- Columbia University Medical Center, New York, NY
| | - R Kukafka
- Columbia University Medical Center, New York, NY
| | - KD Crew
- Columbia University Medical Center, New York, NY
| |
Collapse
|
19
|
Ali-Shaw T, Ueng WA, Trivedi MS, Yi H, David RR, Vanegas A, Vargas JM, Sandoval R, Wood J, Kukafka R, Crew KD. Abstract P5-10-01: Adherence to healthy lifestyle behaviors in a predominantly Hispanic population of women undergoing screening mammography. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-10-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was not presented at the symposium.
Collapse
Affiliation(s)
- T Ali-Shaw
- Columbia University Medical Center; Teachers College, Columbia University
| | - WA Ueng
- Columbia University Medical Center; Teachers College, Columbia University
| | - MS Trivedi
- Columbia University Medical Center; Teachers College, Columbia University
| | - H Yi
- Columbia University Medical Center; Teachers College, Columbia University
| | - RR David
- Columbia University Medical Center; Teachers College, Columbia University
| | - A Vanegas
- Columbia University Medical Center; Teachers College, Columbia University
| | - JM Vargas
- Columbia University Medical Center; Teachers College, Columbia University
| | - R Sandoval
- Columbia University Medical Center; Teachers College, Columbia University
| | - J Wood
- Columbia University Medical Center; Teachers College, Columbia University
| | - R Kukafka
- Columbia University Medical Center; Teachers College, Columbia University
| | - KD Crew
- Columbia University Medical Center; Teachers College, Columbia University
| |
Collapse
|
20
|
Mundi PS, Lee S, Chi D, Bhardwaj A, Makower D, Cigler T, Crew KD, Hershman DL, Califano A, Silva J, Kalinsky KM. Abstract P4-21-37: Phase I trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-21-37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Preclinical and clinical studies suggest that trastuzumab resistance in HER2 amplified breast cancer (HER2+ BC) is mediated by cross-activation of alternative signaling pathways. Computational analysis and pooled whole-genome RNAi screens in HER2 transformed BC cell lines identified the IL6/JAK2/STAT3 axis as a master regulator pathway. The combination of trastuzumab plus ruxolitinib, a JAK1/JAK2 inhibitor, demonstrated synergistic tumor growth inhibition in mouse xenografts of HER2 transformed BC cell lines. These data provide the rationale for studying the efficacy of ruxolitinib and trastuzumab in a clinical trial.
Design
This is a multi-center, open-label, phase I/II trial of ruxolitinib plus trastuzumab in patients (pts) with HER2+ metastatic BC (MBC) who have progressed on >2 HER2-directed therapies in the metastatic setting (including trastuzumab, pertuzumab and T-DM1). The phase I is an adaptive design with 10 pts, using the time-to-event continual reassessment method to determine the recommended phase II dose. Phase II will be a non-randomized, open-label trial with 30 evaluable pts. The duration of a treatment cycle is 21 days, with trastuzumab given on Day 1 and ruxolitinib taken orally twice daily continuously. The primary endpoint of phase I is to determine the maximum tolerated dose of the drug combination. The phase I dose range for ruxolitinib is 10-25 mg BID (dose level 0: 20 mg BID). Response is assessed by imaging every 9 weeks. Blood samples and optional tissue biopsies are obtained for biomarker analysis at the following time points: pre-treatment, on-treatment C2D1, and at progression.
Results
Phase I started accrual in the fall of 2014. The trial has accrued 12 patients, with 9 evaluable and 3 non-evaluable patients. Of the evaluable patients, the mean age was 55.9 (range 32-69). Of these, 7 were postmenopausal (78%) 5/9 (56%) were estrogen receptor positive, and all had measurable disease. The mean number of prior lines of therapy in the metastatic setting was 5.6 (range: 3-8), including a mean of 3.2 (range: 2-5) prior regimens containing HER2 targeted therapies. As of 6/12/16, 2 patients remain on therapy. As this is an adaptive design, efficacy and drug tolerability will not be mentioned in this abstract to not bias the ongoing analysis. However, we anticipate that by SABCS 2016, 10 evaluable patients will have completed the DLT period – at which point, complete data will be presented.
Conclusion
Ruxolitinib plus trastuzumab is a novel, non-chemotherapy containing regimen. The phase I analysis is ongoing. We plan on reporting full safety/tolerability and efficacy data once 10 evaluable patients have completed the phase I (9/10 have currently completed DLT period). Given an early signal in HER2+ breast cancer, in this heavily pretreated population we will proceed directly to a phase II trial with the combination.
Citation Format: Mundi PS, Lee S, Chi D, Bhardwaj A, Makower D, Cigler T, Crew KD, Hershman DL, Califano A, Silva J, Kalinsky KM. Phase I trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-21-37.
Collapse
Affiliation(s)
- PS Mundi
- Columbia University Medical Center, New York, NY; Food and Drug Administration; Mount Sinai School of Medicine, New York, NY; Albert Einstein College of Medicine, Bronx, NY; Weill Cornell Medical Center, New York, NY
| | - S Lee
- Columbia University Medical Center, New York, NY; Food and Drug Administration; Mount Sinai School of Medicine, New York, NY; Albert Einstein College of Medicine, Bronx, NY; Weill Cornell Medical Center, New York, NY
| | - D Chi
- Columbia University Medical Center, New York, NY; Food and Drug Administration; Mount Sinai School of Medicine, New York, NY; Albert Einstein College of Medicine, Bronx, NY; Weill Cornell Medical Center, New York, NY
| | - A Bhardwaj
- Columbia University Medical Center, New York, NY; Food and Drug Administration; Mount Sinai School of Medicine, New York, NY; Albert Einstein College of Medicine, Bronx, NY; Weill Cornell Medical Center, New York, NY
| | - D Makower
- Columbia University Medical Center, New York, NY; Food and Drug Administration; Mount Sinai School of Medicine, New York, NY; Albert Einstein College of Medicine, Bronx, NY; Weill Cornell Medical Center, New York, NY
| | - T Cigler
- Columbia University Medical Center, New York, NY; Food and Drug Administration; Mount Sinai School of Medicine, New York, NY; Albert Einstein College of Medicine, Bronx, NY; Weill Cornell Medical Center, New York, NY
| | - KD Crew
- Columbia University Medical Center, New York, NY; Food and Drug Administration; Mount Sinai School of Medicine, New York, NY; Albert Einstein College of Medicine, Bronx, NY; Weill Cornell Medical Center, New York, NY
| | - DL Hershman
- Columbia University Medical Center, New York, NY; Food and Drug Administration; Mount Sinai School of Medicine, New York, NY; Albert Einstein College of Medicine, Bronx, NY; Weill Cornell Medical Center, New York, NY
| | - A Califano
- Columbia University Medical Center, New York, NY; Food and Drug Administration; Mount Sinai School of Medicine, New York, NY; Albert Einstein College of Medicine, Bronx, NY; Weill Cornell Medical Center, New York, NY
| | - J Silva
- Columbia University Medical Center, New York, NY; Food and Drug Administration; Mount Sinai School of Medicine, New York, NY; Albert Einstein College of Medicine, Bronx, NY; Weill Cornell Medical Center, New York, NY
| | - KM Kalinsky
- Columbia University Medical Center, New York, NY; Food and Drug Administration; Mount Sinai School of Medicine, New York, NY; Albert Einstein College of Medicine, Bronx, NY; Weill Cornell Medical Center, New York, NY
| |
Collapse
|
21
|
Mundi PS, Codruta C, Accordino MK, Sparano J, Andreopoulou E, Vadhat LT, Tiersten A, Esteva F, O'Regan R, Jain S, Mayer I, Forero A, Crew KD, Hershman DL, Kalinsky KM. Abstract OT2-01-19: A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot2-01-19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Cyclin dependent kinase 4 and 6 inhibitors (CDK4/6i), including palbociclib and ribociclib (R), have demonstrated remarkable benefit in progression free survival (PFS) in patients (pts) with hormone receptor positive (HR+), HER2- metastatic breast cancer (MBC) when combined with anti-estrogen therapy. Switching between anti-estrogen therapies at disease progression is standard of care in the treatment of HR+ MBC. We evaluate the strategy of switching anti-estrogen therapy to fulvestrant (F) and maintaining CDK4/6 inhibition with R in pts with HR+, HER2- MBC who have progressed on an aromatase inhibitor (AI) + CDK4/6i.
Trial Design
Phase II, multi-center, randomized, double-blind, placebo-controlled trial to evaluate F +/- R in pts with HR+, HER2- MBC who have previously progressed on any AI + CDK4/6i. Pts can be screened and registered at two different time points:
Scenario 1: Before receiving any CDK4/6i
Scenario 2: At the time of progression of disease (POD) while being treated with an AI + CDK4/6i
In scenario 1, the study will provide pts with letrozole + R, but pts will not be randomized until they demonstrate POD. At randomization, pts will be assigned 1:1 to either a) F + R or b) F + placebo, with treatment given in 4-week cycles. F will be given as a 500 mg dose intramuscularly every 2 weeks for 3 times and then every 4 weeks, as per standard of care. R or placebo will be given orally at 600 mg daily, 3 weeks on/1 week off. CT scans and bone scan are to be performed prior to every third cycle. Serum and whole blood samples and optional tissue biopsies for biomarker assessment will be performed prior to study treatment (scenario 1), prior to randomization to R +/- F, and when the patient goes off study.
Main Eligibility Criteria:
1. Age ≥ 18 years with unresectable or metastatic BC
2. Estrogen and/or progesterone receptor positive, HER2 negative, as per ASCO-CAP
3. Postmenopausal status or receiving ovarian suppression
4. Measurable or unmeasurable disease; stable CNS disease allowed
5. No clinically significant cardiac disease
6. No concomitant CYP3A4/5 inducer or inhibitor
Specific Aims
Primary: Progression free survival (PFS), defined as the time from randomization to POD or death.
Secondary: Objective response rate (ORR), clinical benefit rate (CBR = ORR + stable disease rate), overall survival (OS), and duration of response. Pts in scenario 1 will also be assessed for PFS, OS, CBR, and safety while receiving AI + R (pre-randomization).
Biomarker assessment will include amplification of cyclin D1 and cyclin E, phosphoRb and TK1 expression, Rb1 and p16 loss, and ctDNA for ESR1 and PIK3CA mutations.
Target Accrual
132 pts accrued from 11 academic medical centers in the U.S, with a goal of completing accrual in two years (∼60 to 72 pts in each scenario).
Statistical Methods
Assuming a median PFS of 3.8 months with F alone, we predict that F + R will lead to a median PFS of at least 6.5 months. A one-sided log-rank test with a sample size of N=120 and alpha=0.025, achieves 80% power to detect a difference in PFS of 2.7 months. N=132 pts allows for a 10% drop-out rate.
Citation Format: Mundi PS, Codruta C, Accordino MK, Sparano J, Andreopoulou E, Vadhat LT, Tiersten A, Esteva F, O'Regan R, Jain S, Mayer I, Forero A, Crew KD, Hershman DL, Kalinsky KM. A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT2-01-19.
Collapse
Affiliation(s)
- PS Mundi
- Columbia University Medical Center, New York, NY; Albert Einstein College of Medicine, New York, NY; Weill Cornell Medical Center, New York, NY; Mount Sinai School of Medicine, New York, NY; NYU Medical Center, New York, NY; University of Wisconsin School of Medicine, Madison, WI; Northwestern, Chicago, IL; Vanderbilt-Ingram Cancer Center, Nashville, TN; University of Alabama-Birmingham, Birmingham, AL
| | - C Codruta
- Columbia University Medical Center, New York, NY; Albert Einstein College of Medicine, New York, NY; Weill Cornell Medical Center, New York, NY; Mount Sinai School of Medicine, New York, NY; NYU Medical Center, New York, NY; University of Wisconsin School of Medicine, Madison, WI; Northwestern, Chicago, IL; Vanderbilt-Ingram Cancer Center, Nashville, TN; University of Alabama-Birmingham, Birmingham, AL
| | - MK Accordino
- Columbia University Medical Center, New York, NY; Albert Einstein College of Medicine, New York, NY; Weill Cornell Medical Center, New York, NY; Mount Sinai School of Medicine, New York, NY; NYU Medical Center, New York, NY; University of Wisconsin School of Medicine, Madison, WI; Northwestern, Chicago, IL; Vanderbilt-Ingram Cancer Center, Nashville, TN; University of Alabama-Birmingham, Birmingham, AL
| | - J Sparano
- Columbia University Medical Center, New York, NY; Albert Einstein College of Medicine, New York, NY; Weill Cornell Medical Center, New York, NY; Mount Sinai School of Medicine, New York, NY; NYU Medical Center, New York, NY; University of Wisconsin School of Medicine, Madison, WI; Northwestern, Chicago, IL; Vanderbilt-Ingram Cancer Center, Nashville, TN; University of Alabama-Birmingham, Birmingham, AL
| | - E Andreopoulou
- Columbia University Medical Center, New York, NY; Albert Einstein College of Medicine, New York, NY; Weill Cornell Medical Center, New York, NY; Mount Sinai School of Medicine, New York, NY; NYU Medical Center, New York, NY; University of Wisconsin School of Medicine, Madison, WI; Northwestern, Chicago, IL; Vanderbilt-Ingram Cancer Center, Nashville, TN; University of Alabama-Birmingham, Birmingham, AL
| | - LT Vadhat
- Columbia University Medical Center, New York, NY; Albert Einstein College of Medicine, New York, NY; Weill Cornell Medical Center, New York, NY; Mount Sinai School of Medicine, New York, NY; NYU Medical Center, New York, NY; University of Wisconsin School of Medicine, Madison, WI; Northwestern, Chicago, IL; Vanderbilt-Ingram Cancer Center, Nashville, TN; University of Alabama-Birmingham, Birmingham, AL
| | - A Tiersten
- Columbia University Medical Center, New York, NY; Albert Einstein College of Medicine, New York, NY; Weill Cornell Medical Center, New York, NY; Mount Sinai School of Medicine, New York, NY; NYU Medical Center, New York, NY; University of Wisconsin School of Medicine, Madison, WI; Northwestern, Chicago, IL; Vanderbilt-Ingram Cancer Center, Nashville, TN; University of Alabama-Birmingham, Birmingham, AL
| | - F Esteva
- Columbia University Medical Center, New York, NY; Albert Einstein College of Medicine, New York, NY; Weill Cornell Medical Center, New York, NY; Mount Sinai School of Medicine, New York, NY; NYU Medical Center, New York, NY; University of Wisconsin School of Medicine, Madison, WI; Northwestern, Chicago, IL; Vanderbilt-Ingram Cancer Center, Nashville, TN; University of Alabama-Birmingham, Birmingham, AL
| | - R O'Regan
- Columbia University Medical Center, New York, NY; Albert Einstein College of Medicine, New York, NY; Weill Cornell Medical Center, New York, NY; Mount Sinai School of Medicine, New York, NY; NYU Medical Center, New York, NY; University of Wisconsin School of Medicine, Madison, WI; Northwestern, Chicago, IL; Vanderbilt-Ingram Cancer Center, Nashville, TN; University of Alabama-Birmingham, Birmingham, AL
| | - S Jain
- Columbia University Medical Center, New York, NY; Albert Einstein College of Medicine, New York, NY; Weill Cornell Medical Center, New York, NY; Mount Sinai School of Medicine, New York, NY; NYU Medical Center, New York, NY; University of Wisconsin School of Medicine, Madison, WI; Northwestern, Chicago, IL; Vanderbilt-Ingram Cancer Center, Nashville, TN; University of Alabama-Birmingham, Birmingham, AL
| | - I Mayer
- Columbia University Medical Center, New York, NY; Albert Einstein College of Medicine, New York, NY; Weill Cornell Medical Center, New York, NY; Mount Sinai School of Medicine, New York, NY; NYU Medical Center, New York, NY; University of Wisconsin School of Medicine, Madison, WI; Northwestern, Chicago, IL; Vanderbilt-Ingram Cancer Center, Nashville, TN; University of Alabama-Birmingham, Birmingham, AL
| | - A Forero
- Columbia University Medical Center, New York, NY; Albert Einstein College of Medicine, New York, NY; Weill Cornell Medical Center, New York, NY; Mount Sinai School of Medicine, New York, NY; NYU Medical Center, New York, NY; University of Wisconsin School of Medicine, Madison, WI; Northwestern, Chicago, IL; Vanderbilt-Ingram Cancer Center, Nashville, TN; University of Alabama-Birmingham, Birmingham, AL
| | - KD Crew
- Columbia University Medical Center, New York, NY; Albert Einstein College of Medicine, New York, NY; Weill Cornell Medical Center, New York, NY; Mount Sinai School of Medicine, New York, NY; NYU Medical Center, New York, NY; University of Wisconsin School of Medicine, Madison, WI; Northwestern, Chicago, IL; Vanderbilt-Ingram Cancer Center, Nashville, TN; University of Alabama-Birmingham, Birmingham, AL
| | - DL Hershman
- Columbia University Medical Center, New York, NY; Albert Einstein College of Medicine, New York, NY; Weill Cornell Medical Center, New York, NY; Mount Sinai School of Medicine, New York, NY; NYU Medical Center, New York, NY; University of Wisconsin School of Medicine, Madison, WI; Northwestern, Chicago, IL; Vanderbilt-Ingram Cancer Center, Nashville, TN; University of Alabama-Birmingham, Birmingham, AL
| | - KM Kalinsky
- Columbia University Medical Center, New York, NY; Albert Einstein College of Medicine, New York, NY; Weill Cornell Medical Center, New York, NY; Mount Sinai School of Medicine, New York, NY; NYU Medical Center, New York, NY; University of Wisconsin School of Medicine, Madison, WI; Northwestern, Chicago, IL; Vanderbilt-Ingram Cancer Center, Nashville, TN; University of Alabama-Birmingham, Birmingham, AL
| |
Collapse
|
22
|
Kalinsky K, Zheng T, Hibshoosh H, Du X, Mundi P, Yang J, Refice S, Feldman SM, Taback B, Connolly E, Crew KD, Maurer MA, Hershman DL. Proteomic modulation in breast tumors after metformin exposure: results from a "window of opportunity" trial. Clin Transl Oncol 2016; 19:180-188. [PMID: 27305912 DOI: 10.1007/s12094-016-1521-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2016] [Accepted: 05/19/2016] [Indexed: 12/29/2022]
Abstract
PURPOSE Reverse Phase Protein Array (RPPA) is a high-throughput antibody-based technique to assess cellular protein activity. The goal of this study was to assess protein marker changes by RPPA in tumor tissue from a pre-surgical metformin trial in women with operable breast cancer (BC). METHODS In an open-label trial, metformin 1500-mg PO daily was administered prior to resection in 35 non-diabetic patients with stage 0-III BC, body mass index ≥25 kg/m2. For RPPA, formalin-fixed paraffin-embedded (FFPE) samples were probed with 160 antibodies. Paired and two-sample t-tests were performed (p ≤ 0.05). Multiple comparisons were adjusted for by fixing the false discovery rate at 25 %. We evaluated whether pre- and post-metformin changes of select markers by RPPA were identified by immunohistochemistry (IHC) in these samples. We also assessed for these changes by western blot in metformin-treated BC cell lines. RESULTS After adjusting for multiple comparisons in the 32 tumors from metformin-treated patients vs. 34 untreated historical controls, 11 proteins were significantly different between cases vs. CONTROLS increases in Raptor, C-Raf, Cyclin B1, Cyclin D1, TRFC, and Syk; and reductions in pMAPKpT202,Y204, JNKpT183,pT185, BadpS112, PKC.alphapS657, and SrcpY416. Cyclin D1 change after metformin by IHC was not observed. In cell lines, reductions in JNKpT183 and BadpS112 were seen, with no change in Cyclin D1 or Raptor. CONCLUSIONS These results suggest that metformin modulates apoptosis/cell cycle, cell signaling, and invasion/motility. These findings should be assessed in larger metformin trials. If confirmed, associations between these changes and BC clinical outcome should be evaluated. CLINICALTRIALS. GOV IDENTIFIER NCT00930579.
Collapse
Affiliation(s)
- K Kalinsky
- Department of Medicine, College of Physicians and Surgeons, Columbia University Medical Center, New York, USA. .,Herbert Irving Comprehensive Cancer Center, Columbia University, 161 Fort Washington Avenue, 10th Floor, Room 1069, New York, USA.
| | - T Zheng
- Department of Statistics, Columbia University, New York, USA
| | - H Hibshoosh
- Herbert Irving Comprehensive Cancer Center, Columbia University, 161 Fort Washington Avenue, 10th Floor, Room 1069, New York, USA.,Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University Medical Center, New York, USA
| | - X Du
- Herbert Irving Comprehensive Cancer Center, Columbia University, 161 Fort Washington Avenue, 10th Floor, Room 1069, New York, USA
| | - P Mundi
- Department of Medicine, College of Physicians and Surgeons, Columbia University Medical Center, New York, USA
| | - J Yang
- Department of Medicine, College of Physicians and Surgeons, Columbia University Medical Center, New York, USA
| | - S Refice
- Department of Medicine, College of Physicians and Surgeons, Columbia University Medical Center, New York, USA
| | - S M Feldman
- Herbert Irving Comprehensive Cancer Center, Columbia University, 161 Fort Washington Avenue, 10th Floor, Room 1069, New York, USA.,Department of Surgery, College of Physicians and Surgeons, Columbia University Medical Center, New York, USA
| | - B Taback
- Herbert Irving Comprehensive Cancer Center, Columbia University, 161 Fort Washington Avenue, 10th Floor, Room 1069, New York, USA.,Department of Surgery, College of Physicians and Surgeons, Columbia University Medical Center, New York, USA
| | - E Connolly
- Herbert Irving Comprehensive Cancer Center, Columbia University, 161 Fort Washington Avenue, 10th Floor, Room 1069, New York, USA.,Department of Radiation Oncology, College of Physicians and Surgeons, Columbia University Medical Center, New York, USA
| | - K D Crew
- Department of Medicine, College of Physicians and Surgeons, Columbia University Medical Center, New York, USA.,Herbert Irving Comprehensive Cancer Center, Columbia University, 161 Fort Washington Avenue, 10th Floor, Room 1069, New York, USA.,Department of Epidemiology and Biostatistics, Mailman School of Public Health, Columbia University, New York, USA
| | - M A Maurer
- Department of Medicine, College of Physicians and Surgeons, Columbia University Medical Center, New York, USA.,Herbert Irving Comprehensive Cancer Center, Columbia University, 161 Fort Washington Avenue, 10th Floor, Room 1069, New York, USA
| | - D L Hershman
- Department of Medicine, College of Physicians and Surgeons, Columbia University Medical Center, New York, USA.,Herbert Irving Comprehensive Cancer Center, Columbia University, 161 Fort Washington Avenue, 10th Floor, Room 1069, New York, USA.,Department of Epidemiology and Biostatistics, Mailman School of Public Health, Columbia University, New York, USA
| |
Collapse
|
23
|
Trivedi MS, Tang EY, Kukufka R, Chung WK, David R, Respler L, Leifer S, Schechter I, Crew KD. Abstract P2-09-23: Factors associated with BRCA genetic testing intention and uptake among Orthodox Jewish women. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-09-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Ashkenazi Jews have a 1 in 40 prevalence of carrying a BRCA1/2 mutation, mainly due to 3 founder mutations. Prior literature suggests that population-based genetic testing among Ashkenazi Jews is cost-effective and may detect over 50% more mutation carriers than family history-based screening. Orthodox Jewish women are an understudied population with unique social, cultural, and religious factors that may influence BRCA genetic testing. The aim of our study was to examine factors associated with BRCA genetic testing intention/uptake among the Orthodox Jewish community.
Methods: A one-time online survey was distributed to Orthodox Jewish women by 3 shuls from Washington Heights, NY (53% response rate) and through additional referrals. The questionnaire obtained information regarding demographics, breast cancer risk factors, genetic testing knowledge, decision self-efficacy, perceived breast cancer risk, breast cancer worry, and religious and cultural factors affecting medical decision-making. The Tyrer-Cuzick model was used to calculate lifetime breast cancer risk and accurate risk perception was defined as within +/-10% of actual lifetime risk. Descriptive statistics and multivariable logistic regression models were used to identify independent predictors of genetic testing intention/uptake.
Results: Among 342 evaluable participants, median age was 26 years (range, 19-77); 92% were Ashkenazi and 8% Ashkenazi/Sephardi; 98% had a college education, including 47% with post-graduate degrees. Despite being highly educated, only 54% of women had adequate genetic testing knowledge. Median lifetime breast cancer risk was 16% (range, 2.3-60.9) and only 44% had accurate breast cancer risk perceptions. Although 48% had a family history of breast cancer and 16% had a relative that tested positive for BRCA1/2 mutation, only 5% had undergone BRCA testing while 48% had the intention of undergoing genetic testing. Higher lifetime breast cancer risk, high decision self-efficacy regarding genetic testing, overestimation of breast cancer risk, and increased breast cancer worry were associated with genetic testing intention/uptake. The most important factors in the decision to have BRCA testing were to help prevent dying of cancer (55%), to help prevent getting cancer (54%), and effect on children (40%).
Multivariable analysis of factors associated with BRCA genetic testing intention/uptake OR95% CIp-valueDecision Self-Efficacy (range, 0 [not confident] - 4 [very confident])1.41.02-1.980.038Actual Lifetime Breast Cancer Risk (range, 0 - 100%)1.11.03-1.100.0005Accuracy in Breast Cancer Risk Perception Accurate (referent)1.0--Underestimate1.20.50-2.850.691Overestimate2.61.45-4.610.001Breast Cancer Worry (range, 1 [none] - 7 [worry all of the time])1.51.18-1.980.001
Conclusions: By understanding the religious and cultural issues regarding genetic testing in the Orthodox Jewish community, we can develop targeted interventions designed to enhance decision self-efficacy and improve accuracy of breast cancer risk perceptions to decrease unnecessary worry. This may in turn increase informed decision-making about BRCA genetic testing and implementation of cancer prevention strategies among Ashkenazi Jews.
Citation Format: Trivedi MS, Tang EY, Kukufka R, Chung WK, David R, Respler L, Leifer S, Schechter I, Crew KD. Factors associated with BRCA genetic testing intention and uptake among Orthodox Jewish women. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-09-23.
Collapse
Affiliation(s)
- MS Trivedi
- College of Physicians and Surgeons, Columbia University, NY, NY; Mailman School of Public Health, Columbia University, NY, NY; Institute for Applied Research and Community Collaboration (ARCC), Spring Valley, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, NY, NY
| | - EY Tang
- College of Physicians and Surgeons, Columbia University, NY, NY; Mailman School of Public Health, Columbia University, NY, NY; Institute for Applied Research and Community Collaboration (ARCC), Spring Valley, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, NY, NY
| | - R Kukufka
- College of Physicians and Surgeons, Columbia University, NY, NY; Mailman School of Public Health, Columbia University, NY, NY; Institute for Applied Research and Community Collaboration (ARCC), Spring Valley, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, NY, NY
| | - WK Chung
- College of Physicians and Surgeons, Columbia University, NY, NY; Mailman School of Public Health, Columbia University, NY, NY; Institute for Applied Research and Community Collaboration (ARCC), Spring Valley, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, NY, NY
| | - R David
- College of Physicians and Surgeons, Columbia University, NY, NY; Mailman School of Public Health, Columbia University, NY, NY; Institute for Applied Research and Community Collaboration (ARCC), Spring Valley, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, NY, NY
| | - L Respler
- College of Physicians and Surgeons, Columbia University, NY, NY; Mailman School of Public Health, Columbia University, NY, NY; Institute for Applied Research and Community Collaboration (ARCC), Spring Valley, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, NY, NY
| | - S Leifer
- College of Physicians and Surgeons, Columbia University, NY, NY; Mailman School of Public Health, Columbia University, NY, NY; Institute for Applied Research and Community Collaboration (ARCC), Spring Valley, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, NY, NY
| | - I Schechter
- College of Physicians and Surgeons, Columbia University, NY, NY; Mailman School of Public Health, Columbia University, NY, NY; Institute for Applied Research and Community Collaboration (ARCC), Spring Valley, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, NY, NY
| | - KD Crew
- College of Physicians and Surgeons, Columbia University, NY, NY; Mailman School of Public Health, Columbia University, NY, NY; Institute for Applied Research and Community Collaboration (ARCC), Spring Valley, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, NY, NY
| |
Collapse
|
24
|
Kalinsky K, Chi DC, Lee S, Bhardwaj A, Makower D, Cigler T, Crew KD, Hershman DL, Califano A, Silva J, Maurer M. Abstract OT3-01-06: Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-ot3-01-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Integrated analysis of whole genome RNAi screening with computationally reverse engineered interactome models identified IL6/JAK/STAT as a master regulator pathway essential for growth of ErbB2/HER2 positive breast cancer. Ruxolitinib (R), FDA-approved treatment for myelofibrosis, inhibits JAK1 and JAK2. The combination of R plus Trastuzumab (T) is synergistic in tumor growth inhibition in mouse xenografts of HER2 amplified breast cancer cell lines. These data provide a strong rationale for studying the efficacy of combination R and T in a clinical trial.
Trial Design:
A multi-center, open-label, phase I/II (P1/2) trial of R plus T in HER2+ metastatic breast cancer (MBC) who have progressed on T-based therapy. P1 will be an adaptive design with 10 patients, using the time-to-event continual reassessment method. The recommended P2 dose (RP2D) will be used in a non-randomized, open-label P2 trial with 30 evaluable patients (pts). Given the anticipated limited overlapping toxicities, approximately 36 pts (range: 32-40) are expected for the P1/2. The duration of a treatment cycle will be 21 days. R will be taken orally twice a day continuously. The P1 dosing range will be 10-25 mg BID (dose level 0: 20 mg BID). T will be administered on Day 1 of each cycle at standard dosing. Objective Response Rate (ORR) will be assessed by imaging every 9 weeks. Blood samples will be obtained for biomarker analysis, pre-treatment, on-treatment on C2D1, and then at progression. Pre-treatment biopsies from archival tissue or new biopsy, on treatment biopsy on C2D1, and upon progression of disease will be discussed with pts with accessible disease.
Main Eligibility Criteria:
1. HER2 positive MBC
2. Progression on HER2-directed therapy in metastatic setting, including Pertuzumab and T-DM1
3. Measurable or non-measurable disease
4. LVEF great than 50%
5. No history of prior JAK2 inhibitor
6. No HIV-positive or active infection
7. No concurrent medications that are potent CYP3A4 inhibitor or inducer
Specific Aims:
1. Primary: P1: MTD of combined R + T. P2: Progression Free Survival (PFS)
2. Secondary: a) Clinical: ORR, clinical benefit rate (CBR), and tolerability. Pts will be stratified by hormone receptor (HR) status to explore differences in efficacy between HR+ and HR-.
b) Explore potential predictive tumor and blood-based predictive biomarkers at baseline, on treatment, and progression: (tumor: pSTAT3 expression); serum: IL-6, IL-8, C-reactive protein; circulating tumor cell pSTAT3 expression; and tumor gene expression.
Statistical Methods:
Assuming a historical PFS of 8 weeks with single-agent agent HER2-targeted therapy in HER2+ MBC after progressing on T-based therapy, we predict that pts receiving the combination of R plus T will have a PFS of at least 13 weeks. With a 2-sided alpha of 0.05, we have 80% power to detect a difference with 30 pts.
Target Accrual:
Sample Size: 32-40 pts; projected over 2 years at 4 sites: Columbia, Einstein, Mount Sinai, and Cornell. Trial accruing since Fall 2014.
Citation Format: Kalinsky K, Chi D-C, Lee S, Bhardwaj A, Makower D, Cigler T, Crew KD, Hershman DL, Califano A, Silva J, Maurer M. Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr OT3-01-06.
Collapse
Affiliation(s)
- K Kalinsky
- New York Presbyterian - Columbia University Medical Center; Mount Sinai Medical Center; Montefiore Medical Center; New York Presbyterian - Weill Cornell Medical Center
| | - D-C Chi
- New York Presbyterian - Columbia University Medical Center; Mount Sinai Medical Center; Montefiore Medical Center; New York Presbyterian - Weill Cornell Medical Center
| | - S Lee
- New York Presbyterian - Columbia University Medical Center; Mount Sinai Medical Center; Montefiore Medical Center; New York Presbyterian - Weill Cornell Medical Center
| | - A Bhardwaj
- New York Presbyterian - Columbia University Medical Center; Mount Sinai Medical Center; Montefiore Medical Center; New York Presbyterian - Weill Cornell Medical Center
| | - D Makower
- New York Presbyterian - Columbia University Medical Center; Mount Sinai Medical Center; Montefiore Medical Center; New York Presbyterian - Weill Cornell Medical Center
| | - T Cigler
- New York Presbyterian - Columbia University Medical Center; Mount Sinai Medical Center; Montefiore Medical Center; New York Presbyterian - Weill Cornell Medical Center
| | - KD Crew
- New York Presbyterian - Columbia University Medical Center; Mount Sinai Medical Center; Montefiore Medical Center; New York Presbyterian - Weill Cornell Medical Center
| | - DL Hershman
- New York Presbyterian - Columbia University Medical Center; Mount Sinai Medical Center; Montefiore Medical Center; New York Presbyterian - Weill Cornell Medical Center
| | - A Califano
- New York Presbyterian - Columbia University Medical Center; Mount Sinai Medical Center; Montefiore Medical Center; New York Presbyterian - Weill Cornell Medical Center
| | - J Silva
- New York Presbyterian - Columbia University Medical Center; Mount Sinai Medical Center; Montefiore Medical Center; New York Presbyterian - Weill Cornell Medical Center
| | - M Maurer
- New York Presbyterian - Columbia University Medical Center; Mount Sinai Medical Center; Montefiore Medical Center; New York Presbyterian - Weill Cornell Medical Center
| |
Collapse
|
25
|
Crew KD, Xiao T, Thomas PS, Terry MB, Maurer M, Kalinsky K, Feldman S, Brafman L, Refice SR, Hershman DL. Safety, Feasibility, and Biomarker Effects of High-Dose Vitamin D Supplementation Among Women at High Risk for Breast Cancer. ACTA ACUST UNITED AC 2015; 2015:1-16. [PMID: 28480224 PMCID: PMC5415303 DOI: 10.19070/2326-3350-si01001] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Vitamin D deficiency is a potentially modifiable risk factor that may be targeted for breast cancer prevention. We examined the safety, feasibility, and biomarker effects of high-dose vitamin D among women at high risk for breast cancer. Forty high-risk women, defined as a 5-year breast cancer risk ≥1.67% per the Gail model, lobular or ductal carcinoma in situ, were assigned to a 1-year intervention of vitamin D3 20,000 IU or 30,000 IU weekly. Participants were monitored for toxicity every 3 months, underwent serial blood draws at baseline, 6 and 12 months, and a digital mammogram at baseline and 12 months. Biomarker endpoints included serum 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1,25(OH)2D], parathyroid hormone (PTH), insulin-like growth factor (IGF-1), IGF binding protein (IGFBP-3), and mammographic density (MD) using Cumulus software. From November 2007 to January 2011, we enrolled 40 women; 37 were evaluable at 6 months and 30 at 12 months. One patient was taken off study for hypercalciuria; otherwise, the intervention was well tolerated. From baseline to 12 months, mean serum 25(OH)D and 1,25(OH)2D rose from 20.0 to 46.9 ng/ml and 69.7 to 98.1 pg/ml, respectively (p<0.01). Serum PTH decreased by 12% at 6 months and IGF-1/IGFBP-3 ratio decreased by 4.3% at 12 months (p<0.05). There was no significant change in MD regardless of menopausal status or dose level. We demonstrated that 1 year of high-dose vitamin D3 was associated with a significant increase in circulating vitamin D levels and favorable effects on IGF signaling, but no significant change in MD.
Collapse
Affiliation(s)
- K D Crew
- Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA.,Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.,Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
| | - T Xiao
- Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA
| | - P S Thomas
- Department of Clinical Cancer Prevention, MD Anderson Cancer Center, Houston, TX, USA
| | - M B Terry
- Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA.,Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
| | - M Maurer
- Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.,Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
| | - K Kalinsky
- Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.,Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
| | - S Feldman
- Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.,Department of Surgery, College of Physicians and Surgeons, Columbia University, New York, NY, USA
| | - L Brafman
- Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
| | - S R Refice
- Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
| | - D L Hershman
- Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA.,Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.,Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
| |
Collapse
|
26
|
Crew KD, Ho KA, Brown P, Greenlee H, Bevers TB, Arun B, Sneige N, Hudis C, McArthur HL, Chang J, Rimawi M, Cornelison TL, Cardelli J, Santella RM, Wang A, Lippman SM, Hershman DL. Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer. J Hum Nutr Diet 2014; 28:272-82. [PMID: 24646362 DOI: 10.1111/jhn.12229] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
BACKGROUND Observational and experimental data support a potential breast cancer chemopreventive effect of green tea. METHODS We conducted an ancillary study using archived blood/urine from a phase IB randomised, placebo-controlled dose escalation trial of an oral green tea extract, Polyphenon E (Poly E), in breast cancer patients. Using an adaptive trial design, women with stage I-III breast cancer who completed adjuvant treatment were randomised to Poly E 400 mg (n = 16), 600 mg (n = 11) and 800 mg (n = 3) twice daily or matching placebo (n = 10) for 6 months. Blood and urine collection occurred at baseline, and at 2, 4 and 6 months. Biological endpoints included growth factor [serum hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF)], lipid (serum cholesterol, triglycerides), oxidative damage and inflammatory biomarkers. RESULTS From July 2007-August 2009, 40 women were enrolled and 34 (26 Poly E, eight placebo) were evaluable for biomarker endpoints. At 2 months, the Poly E group (all dose levels combined) compared to placebo had a significant decrease in mean serum HGF levels (-12.7% versus +6.3%, P = 0.04). This trend persisted at 4 and 6 months but was no longer statistically significant. For the Poly E group, serum VEGF decreased by 11.5% at 2 months (P = 0.02) and 13.9% at 4 months (P = 0.05) but did not differ compared to placebo. At 2 months, there was a trend toward a decrease in serum cholesterol with Poly E (P = 0.08). No significant differences were observed for other biomarkers. CONCLUSIONS Our findings suggest potential mechanistic actions of tea polyphenols in growth factor signalling, angiogenesis and lipid metabolism.
Collapse
Affiliation(s)
- K D Crew
- Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
| | - K A Ho
- Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
| | - P Brown
- University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | - H Greenlee
- Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
| | - T B Bevers
- University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | - B Arun
- University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | - N Sneige
- University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | - C Hudis
- Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - H L McArthur
- Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - J Chang
- The Methodist Hospital Cancer Center, Houston, TX, USA
| | - M Rimawi
- Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA
| | - T L Cornelison
- Divison of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA
| | - J Cardelli
- Louisiana State University Health Sciences Center, Shreveport, LA, USA
| | - R M Santella
- Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
| | - A Wang
- Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
| | - S M Lippman
- University of California San Diego Moores Cancer Center, San Diego, CA, USA
| | - D L Hershman
- Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
| |
Collapse
|
27
|
Greenlee H, Awad D, Crew KD, Kalinsky K, Maurer M, Brafman L, Jayasena R, Tsai WY, Neugut AI, Hershman DL. Abstract P3-08-12: Influence of a clinic-based survivorship intervention on dietary change and lifestyle recommendations among Hispanic and non-Hispanic women following adjuvant therapy for breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-08-12] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: In 2006, the IOM released a report citing the importance of “survivorship plans” to improve quality-of-life. Little has been done to evaluate their efficacy with regard to uptake of dietary and lifestyle recommendations.
METHODS: Women with early-stage breast cancer were randomized within 6 weeks of completing adjuvant therapy to a survivorship intervention or a control group. Randomization was stratified by ethnicity and subjects were not aware that they were randomized. All subjects were provided the NCI publication, “Facing Forward: Life after Cancer Treatment.” The survivorship intervention group also met with a nurse (1 hour) and nutritionist (1 hour) to receive a treatment summary, surveillance and personalized lifestyle recommendations, based on guidelines from the American Cancer Society and American Institute for Cancer Research. At baseline, 3 and 6 months, both groups completed questionnaires on diet, lifestyle, and perceived health. Linear regression analyses adjusted for ethnicity evaluated the effects of the intervention on comprehension and uptake of lifestyle recommendations. Additional models were run to evaluate the interaction between intervention and ethnicity.
RESULTS: Among 126 women (60 control group, 66 survivorship intervention) mean age was 54 yrs, 48% were Hispanic, and randomized groups were well-balanced by baseline characteristics. Of note, at baseline, compared to non-Hispanics, Hispanics reported lower SES, poorer knowledge of healthy lifestyle behaviors (e.g., diet, physical activity, weight, dietary supplements), lower intake of fruits and vegetables, less recreational physical activity, lower consumption of alcohol, and a lower overall health rating (all P<0.05). After adjusting for ethnicity, at month 3 the intervention group compared to the control group reported greater knowledge of how to eat a healthy diet (P = 0.047), greater knowledge of appropriate use of dietary supplements (P = 0.006), higher levels of physical activity (P = 0.03), and higher intake of fish (P = 0.005). At month 6, the only difference that persisted was greater knowledge of a healthy diet (P = 0.01). In models assessing an interaction between intervention condition and ethnicity, compared to Hispanics, the intervention had a stronger effect on increasing non-Hispanics’ belief that a healthy diet was important to prevent breast cancer recurrence (P = 0.02).
CONCLUSIONS: Compared to only receiving written survivorship materials, a survivorship intervention that included written materials plus a 1 hour personalized lifestyle counseling session was associated with short-term increased knowledge of lifestyle recommendations, change in physical activity and change in dietary behaviors among a multi-ethnic group of breast cancer survivors. Behavioral effects were not observed beyond 3 months. A single 1 hour lifestyle consultation is likely not enough to achieve and maintain lifestyle recommendations. To facilitate long-term behavioral change among breast cancer survivors in the adjuvant setting, culturally competent behavioral interventions should be developed to increase knowledge of and the capabilities needed to meet lifestyle recommendations.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-08-12.
Collapse
Affiliation(s)
- H Greenlee
- Columbia University Medical Center, New York, NY
| | - D Awad
- Columbia University Medical Center, New York, NY
| | - KD Crew
- Columbia University Medical Center, New York, NY
| | - K Kalinsky
- Columbia University Medical Center, New York, NY
| | - M Maurer
- Columbia University Medical Center, New York, NY
| | - L Brafman
- Columbia University Medical Center, New York, NY
| | - R Jayasena
- Columbia University Medical Center, New York, NY
| | - WY Tsai
- Columbia University Medical Center, New York, NY
| | - AI Neugut
- Columbia University Medical Center, New York, NY
| | - DL Hershman
- Columbia University Medical Center, New York, NY
| |
Collapse
|
28
|
Kalinsky K, Baer L, Tsai WY, Ngan MC, Feldman SM, Taback B, Ananthakrishnan P, Chen-Seetoo M, Hibshoosh H, Crew KD, Maurer MA, Hershman DL. Abstract OT2-6-06: Pre-surgical “window of opportunity” trial of metformin and atorvastatin in newly diagnosed operable breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-ot2-6-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast cancer requires energy homeostasis shifts with enhanced anabolism to enable rapid growth and continued proliferation. The main energy regulatory system is the AMP-activated kinase (AMPK) pathway triggered by changes in the AMP/ATP ratio. AMPK pathway closely interacts with the PI3K/AKT signaling pathway, with both pathways affecting downstream function of the master regulator mTOR. “Window of opportunity” studies with metformin alone, an AMPK inhibitor, have resulted in mixed results in reducing tumor proliferation in women with early-stage operable breast cancer. Reduction in tumor proliferation has been demonstrated with statins alone (i.e. HMG CoA reductase inhibitors) in pre-surgical trials. Dual therapy with both metformin and atorvastatin demonstrate synergistic activity in preclinical studies in cancer cell lines, showing enhanced anti-proliferative effect. The purpose of this study is to determine the effects of dual therapy with metformin and atorvastatin in women with newly diagnosed BC between breast biopsy and surgery.
Trial Design: Patients (n = 40) will receive metformin 1500mg (500 mg am/1000 mg pm) and atorvastatin 80mg pm, for 2-4 weeks following a diagnostic biopsy and prior to surgery (goal: at least 2 weeks). The main eligibility criteria for this open-label, single-institution, pre-surgical trial include operable stage 0-III BC. Patients must have at least 1 cm of tumor based on palpation or imaging to ensure sufficient pre-treatment tissue. Patients not considered for neoadjuvant chemotherapy are eligible. Specific Aims: Our hypothesis is that pre-surgical metformin plus atorvastatin will result in a significant decrease in the tumor proliferation marker Ki-67. Ki-67 will be log-transformed ln(ki-67), per international guidelines. Secondary objectives include evaluation of functional proteomic changes, such as AMPK/mTOR pathway signaling and apoptosis, by reverse phase protein array (RPPA), as well as assessment of changes in serum insulin, lipids, and markers of the insulin growth factor pathway.
Statistical Methods: Paired t-tests will be calculated to assess modulations in ln(ki-67) before and after treatment. Compared to historical control, we will achieve 80% power with 40 patients, anticipating a -0.523 reduction of ln(ki-67) and standard deviation of 1.15 before and after metformin plus statin (significance level, p = 0.05). We will also be comparing changes in ln(ki-67) in the treated patients to historical controls matched by age, stage, and BMI, using a two-sample t-test at level 0.05. Frequency distributions and summary descriptive statistics will be calculated for all other biomarkers in the two groups. Correlations between all biomarkers and changes in Ki-67 proliferation marker will be analyzed in exploratory fashion. We will also explore differences in modulation of tumor proliferation and functional proteomics in grade III tumors as compared to other tumors. We anticipate accrual 2-3 patient/month, completing the trial within 18 months. Contact information: kk2693@columbia.edu.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr OT2-6-06.
Collapse
Affiliation(s)
- K Kalinsky
- Columbia Universtiy Medical Center, New York, NY
| | - L Baer
- Columbia Universtiy Medical Center, New York, NY
| | - WY Tsai
- Columbia Universtiy Medical Center, New York, NY
| | - MC Ngan
- Columbia Universtiy Medical Center, New York, NY
| | - SM Feldman
- Columbia Universtiy Medical Center, New York, NY
| | - B Taback
- Columbia Universtiy Medical Center, New York, NY
| | | | | | - H Hibshoosh
- Columbia Universtiy Medical Center, New York, NY
| | - KD Crew
- Columbia Universtiy Medical Center, New York, NY
| | - MA Maurer
- Columbia Universtiy Medical Center, New York, NY
| | - DL Hershman
- Columbia Universtiy Medical Center, New York, NY
| |
Collapse
|
29
|
Gucalp A, Morris PG, Zhou XK, Giri DD, Iyengar NM, Heckman-Stoddard BM, Dunn B, Garber JE, Crew KD, Hershman DL, Nangia JR, Cook ED, Brown PH, Dannenberg AJ, Hudis CA. Abstract OT3-3-01: A multicenter phase II study of docosahexaenoic acid (DHA) in triple negative breast cancer (TNBC) survivors. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-ot3-3-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The development of effective chemopreventive strategies to reduce the risk of TNBC, is a critical unmet need. Obesity is associated with a chronic inflammatory condition in the white adipose tissue of the breast, characterized microscopically by crown-like structures of the breast (CLS-B). The presence and extent of these lesions is associated with a series of proinflammatory mediators, including tumor necrosis factor-α (TNF-α), cyclooxygenase-2 (COX-2), interleukin-1β (IL-1β) and aromatase. Importantly these proinflammatory mediators are known to be involved in breast carcinogenesis. In translational studies to date, the strongest correlations have been seen between CLS-B and TNF-α. Therefore, we aim to evaluate whether treatment with a dietary supplement, DHA, an omega-3 fatty acid, with potent effects on TNF-α, can decrease obesity-related breast inflammation in women.
Trial design: This is a randomized phase II placebo-controlled, double-blinded study of DHA in overweight/obese patients (pts), defined as body mass index (BMI) ≥25 with a history of TNBC. Pts will receive DHA or placebo twice daily for 24 weeks and will undergo core biopsies from normal (non-irradiated contralateral) breast tissue before and after the treatment to determine whether DHA can decrease obesity-related breast inflammation.
Eligibility: Inclusion criteria: 1) Age ≥ 18. 2) BMI ≥ 25. 3) Completed treatment for stage I-III TNBC ≥ 6 months prior. 4) No clinical evidence of disease. 5) Adequate accessible breast tissue for pre- and post- treatment biopsy, consisting of one breast unaffected by invasive cancer, which has not been radiated or surgically augmented. 6) Adequate organ and bone marrow function. 7) ECOG status ≤2. Exclusion criteria: 1) DHA supplementation. 2) Aspirin/NSAID use in the month preceding and during the trial. 3) Therapeutic anticoagulation. 4) Regular use of statins, steroids, or immunomodulators.
Specific aims: The primary objective is to determine whether treatment with DHA for 24 weeks at 1,000 mg twice daily as compared to placebo reduces normal breast tissue levels of TNF-α in overweight/obese pts with a history of TNBC. The secondary objective is to evaluate the effect of DHA on the change from baseline in levels of the following tissue biomarkers: COX-2, IL-1β, aromatase, and CLS-B. Exploratory endpoints include assessment of age as a predictor of CLS-B and inflammatory biomarkers and the evaluation of red blood cell fatty acid levels as a surrogate of DHA compliance.
Statistical methods: Percent change in TNF-α mRNA levels in normal breast tissue between DHA and placebo arm will be compared using two-sample t-test. If normality assumptions are violated, a two-sample Wilcoxon rank-sum test will be used. With 30 subjects in each arm, we will have 80% power to detect effect size as small as 0.74 at 0.05 significance level using a two-sided, two-sample, Student t-test.
Accrual: A total of 60 evaluable pts will be enrolled. Assuming a 10% dropout rate and 10% non-evaluable rate, up to 76 participants will be randomized in this study. This trial is currently enrolling pts.
Contact information: For more information on this trial, please visit clinicaltrials.gov (NCT01849250) or contact Ayca Gucalp MD (gucalpa@mskcc.org).
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr OT3-3-01.
Collapse
Affiliation(s)
- A Gucalp
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - PG Morris
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - XK Zhou
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - DD Giri
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - NM Iyengar
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - BM Heckman-Stoddard
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - B Dunn
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - JE Garber
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - KD Crew
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - DL Hershman
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - JR Nangia
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - ED Cook
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - PH Brown
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - AJ Dannenberg
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - CA Hudis
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| |
Collapse
|
30
|
Crew KD, Lew DL, Hershman DL, Refice S, Anderson GL, Hortobagyi GN, Goodman GE, Brown PH. Abstract OT3-3-02: Phase IIB randomized double-blind placebo-controlled biomarker modulation study of high dose vitamin D in premenopausal women at high-risk for breast cancer: SWOG S0812. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-ot3-3-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Priorities in breast cancer chemoprevention include developing agents effective against estrogen receptor (ER)-negative breast cancer and validating intermediate biomarkers which correlate with breast cancer risk. Vitamin D is a fat-soluble vitamin which regulates calcium and bone homeostasis, but also has diverse biological effects relevant to breast carcinogenesis. The biologically active form of vitamin D [1,25(OH)D] interacts with the vitamin D receptor (VDR) to modulate cell proliferation, differentiation, apoptosis, and angiogenesis. Epidemiologic data suggests that serum 25(OH)D levels >40-50 ng/ml are associated with a 40-50% reduction in breast cancer risk compared to women with vitamin D deficiency (<20 ng/ml). Given the high prevalence of vitamin D deficiency in the general population, vitamin D3 3000-4000 IU daily would be required to raise 25(OH)D to this putative target level. The central hypothesis of this proposal is that high-dose vitamin D will modulate biomarkers of breast cancer risk.
Trial Design: This trial is a phase IIB, randomized, double-blind, placebo-controlled study of oral vitamin D3 (cholecalciferol) 20,000 IU (2 capsules) weekly for one year in 200 premenopausal women at high-risk for breast cancer. Both groups will be supplemented with a standard dose of vitamin D3 600 IU daily. Participants will undergo a mammogram and optional random core breast biopsy timed within 10 days after the start of their menstrual cycle at baseline and 1 year and blood collections at baseline, 6, and 12 months. Participants will be monitored for toxicity, particularly hypercalcemia and hypercalciuria, every 3 months during the 1-year intervention.
Main Eligibility Criteria: High-risk is defined as a 5-year Gail risk score ≥1.67% or lifetime risk ≥20%, history of atypical hyperplasia, lobular or ductal carcinoma in situ, germline mutations in BRCA1, BRCA2, p53, or PTEN, history of stage I-II breast cancer in remission for >5 years, or baseline mammographic density >50%. Other eligibility criteria include baseline serum 25(OH)D ≤32 ng/ml, normal serum calcium and urine calcium/creatinine ratio, and no history of kidney stones.
Specific Aims: The primary endpoint is change in mammographic density at 12 months compared to baseline between the vitamin D and placebo groups. Secondary exploratory endpoints include breast tissue-based biomarkers (Ki-67, cleaved caspase-3, ER, VDR, and 1α-hydroxylase) and blood-based biomarkers (25(OH)D, 1,25(OH)D, PTH, IGF-1, IGFBP-3, VDR polymorphisms).
Statistical Methods: Power calculations are based on a two-sample comparison of normal deviates, using a 2-sided, 0.05-level test. To be conservative, we assume that 15% will have missing breast density data at 12 months and a 2% difference in mammographic density between intervention and control at 12 months with a the standard deviation for each arm of 4%. With 200 women randomized, the study will have 90% power to detect this difference.
Target Accrual: 200. Sixty-seven patients accrued as of June 2013. Accrual completion expected December 2014.
Contact: Katherine Crew, Columbia University Medical Center, kd59@columbia.edu.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr OT3-3-02.
Collapse
Affiliation(s)
- KD Crew
- Columbia University, New York, NY; SWOG Statistical Center/Fred Hutchinson Cancer Research Center, Seattle, WA; MD Anderson Cancer Center, Houston, TX; Swedish Medical Center Cancer Institute, Seattle, WA
| | - DL Lew
- Columbia University, New York, NY; SWOG Statistical Center/Fred Hutchinson Cancer Research Center, Seattle, WA; MD Anderson Cancer Center, Houston, TX; Swedish Medical Center Cancer Institute, Seattle, WA
| | - DL Hershman
- Columbia University, New York, NY; SWOG Statistical Center/Fred Hutchinson Cancer Research Center, Seattle, WA; MD Anderson Cancer Center, Houston, TX; Swedish Medical Center Cancer Institute, Seattle, WA
| | - S Refice
- Columbia University, New York, NY; SWOG Statistical Center/Fred Hutchinson Cancer Research Center, Seattle, WA; MD Anderson Cancer Center, Houston, TX; Swedish Medical Center Cancer Institute, Seattle, WA
| | - GL Anderson
- Columbia University, New York, NY; SWOG Statistical Center/Fred Hutchinson Cancer Research Center, Seattle, WA; MD Anderson Cancer Center, Houston, TX; Swedish Medical Center Cancer Institute, Seattle, WA
| | - GN Hortobagyi
- Columbia University, New York, NY; SWOG Statistical Center/Fred Hutchinson Cancer Research Center, Seattle, WA; MD Anderson Cancer Center, Houston, TX; Swedish Medical Center Cancer Institute, Seattle, WA
| | - GE Goodman
- Columbia University, New York, NY; SWOG Statistical Center/Fred Hutchinson Cancer Research Center, Seattle, WA; MD Anderson Cancer Center, Houston, TX; Swedish Medical Center Cancer Institute, Seattle, WA
| | - PH Brown
- Columbia University, New York, NY; SWOG Statistical Center/Fred Hutchinson Cancer Research Center, Seattle, WA; MD Anderson Cancer Center, Houston, TX; Swedish Medical Center Cancer Institute, Seattle, WA
| |
Collapse
|
31
|
Sivasubramanian PS, Reimers LL, Greenlee H, Terry MB, Hershman D, Maurer M, Kalinsky K, Awad D, Xiao T, Sandoval R, Alvarez M, Quirarte A, Campbell J, Crew KD. Abstract P5-13-01: Uptake of breast cancer chemoprevention among high-risk women and those with ductal carcinoma in situ. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p5-13-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Chemoprevention with antiestrogens, such as tamoxifen, raloxifene, and aromatase inhibitors (AIs), reduces breast cancer incidence in high-risk women. However, uptake has been poor in the prevention setting. We examined demographic and clinical factors that influenced chemoprevention uptake in women with an elevated Gail risk score (≥1.67%), lobular/ductal carcinoma in situ (LCIS/DCIS), and/or BRCA mutation carriers.
Methods: We enrolled women prospectively without a diagnosis of invasive breast cancer, who were seen for an initial consultation by breast surgery or medical oncology at Columbia University Medical Center. Eligibility for chemoprevention included a 5-year Gail risk ≥1.67%, LCIS, known BRCA1 or BRCA2 mutation, or hormone receptor (HR)-positive DCIS. Demographic and risk factor data were collected from a self-administered baseline questionnaire and clinical data from medical chart review, including prior/current chemoprevention, type of antiestrogen, duration of use, and toxicities. Differences in distribution of risk factors between women who ever took chemoprevention and those who did not were examined using chi-square statistics or Fisher's exact test. We used log-binomial regression models to estimate relative risks (RRs) and 95% confidence intervals (95% CI) using chemoprevention uptake as the dependent variable. A subset of high-risk women completed questionnaires assessing their attitudes towards chemoprevention and perceived risks/benefits.
Results: Among 412 women enrolled between March 2007 and April 2013, 316 (77%) were eligible for chemoprevention. Main reasons for ineligibility included 5-year Gail risk <1.67% (40%), age <35 (24%), HR-negative DCIS (17%), opting for bilateral mastectomies (11%), and medical contraindications (8%). Among those eligible for chemoprevention, median age 53 (26-88); White/Hispanic/Black/Asian/other (%): 55/29/8/7/1; risk category, 5-year Gail risk ≥1.67%/LCIS/DCIS/BRCA mutation (%): 36/22/40/2. Overall, 162 (51%) women started an antiestrogen (72% for DCIS and 37% among high-risk women), including 114 on tamoxifen, 40 on raloxifene, and 11 on an AI. Early discontinuation occurred in 27 (18%) women, but 7 switched to a different antiestrogen. In univariable analysis, postmenopausal status and medical oncology referral were associated with higher chemoprevention uptake. In multivariable analysis, only higher risk was a significant predictor of chemoprevention uptake. Among the subset of women who completed additional questionnaires on attitudes towards chemoprevention, they reported that the most important factors in chemoprevention decision-making included their healthcare provider (50%), results of chemoprevention studies (44%), and knowledge about others’ experience with chemoprevention (44%). The majority (69%) were concerned about side effects, specifically blood clots with tamoxifen and raloxifene and bone fractures with AIs.
Conclusions: In high-risk women seen at an academic breast center, chemoprevention uptake was relatively high compared to the published literature. Further research is needed to determine how the risks and benefits of chemoprevention are best communicated to women to enhance informed decision-making and increase uptake of chemoprevention strategies.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-13-01.
Collapse
Affiliation(s)
| | | | | | - MB Terry
- Columbia University, New York, NY
| | | | - M Maurer
- Columbia University, New York, NY
| | | | - D Awad
- Columbia University, New York, NY
| | - T Xiao
- Columbia University, New York, NY
| | | | | | | | | | - KD Crew
- Columbia University, New York, NY
| |
Collapse
|
32
|
Kalinsky K, Zheng T, Crew KD, Refice S, Feldman SM, Taback B, Hibshoosh H, Su T, Maurer MM, Hershman DL. Abstract P4-15-03: Proteomic modulation in breast tumors after metformin use: Results from a “window of opportunity” trial. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-15-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Laboratory and population studies demonstrate that metformin offers a beneficial breast cancer (BC) effect through reduction of serum insulin levels and changes in cellular protein synthesis and growth, such as AMPK pathway signaling. In a pre-surgical metformin trial of overweight/obese, multi-ethnic BC patients, we reported no difference in tumor proliferation, as measured by ki-67. However, reductions in other biomarkers were observed, including reduction in body mass index (BMI), serum cholesterol, serum insulin, and leptin. Reverse Phase Protein Array (RPPA) is a high-throughput antibody-based technique to assess cellular protein activity in signaling networks. The goal of this study was to assess changes in functional proteomics through RPPA in patients treated in a pre-surgical metformin trial.
Methods: Metformin 1500mg PO daily (500mg am/1000 mg pm) was administered for 2-4 weeks prior to resection in 35 patients with stage 0-III operable BC, BMI ≥ 25 kg/m2, and no history of diabetes. Protein was extracted from pre- and post-metformin paraffin-embedded tumor tissue, denatured by sodium dodecyl sulfate, and printed on nitrocellulose-coated slides. Samples were probed with 160 antibodies. Evaluated antibodies associated with various cellular activities, including PI3K/AKT signaling, HSP90 clients, Src/STAT activity, and apoptosis. We analyzed changes in RPPA parameters in tumor tissue of study patients with those of untreated historical controls, matched by age, BMI, and tumor characteristics. Paired t-test was used to calculate within-group changes in RPPA, and two-sample t-tests were used to compare between-group changes in cases and controls (significance: p ≤ 0.05). Multiple comparisons were adjusted for by fixing the false discovery rate (FDR) at 25%.
Results: Of the 35 metformin-treated patients, 32 were evaluable. The majority were Hispanic (80%). Metformin was administered for a median of 23 days (range: 8-64). Of the invasive BCs (n = 21/35), 80% of patients had HR+/HER2- BC. The 33 historical controls were well-matched. For RPPA, the mean total formalin-fixed paraffin embedded protein concentration was 38.9 ug (SD: 3.3). Of the 160 antibodies, 67 antibodies significantly changed after metformin use in the treated group, including reduction in pAKTS473, pAKTT308, and MTOR (unadjusted). Nineteen antibodies were identified as having between group differences in change from baseline: increase in BadpS112, C-RAF, Claudin-7, Cyclin B1, Cyclin D1, EGFR, HER3 pY1298, Lck, PKC-alphapS657, RAD50, Raptor, Syk, and TRFC; reduction in 14-3-3 epsilon, FOXO3a, JNKpT183, MAPKpT202, MEK1pS217, and SrcpY416. Adjusting for multiple comparisons, the following remain statistically significantly different between cases vs. controls: increase in BadpS112, C-RAF, Cyclin D1, and Raptor; and reduction in JNKpT183. Further assessment of RPPA modulation is ongoing, including changes grouped by signaling pathway and activity, as well as validation by immunohistochemistry.
Conclusions: Compared to controls, metformin use associates with changes in apoptosis, cell signaling, C-RAF, and Raptor. These results should be further validated in larger metformin intervention trials to better define populations who may benefit from this therapy.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-15-03.
Collapse
Affiliation(s)
- K Kalinsky
- Columbia University Medical Center, New York, NY
| | - T Zheng
- Columbia University Medical Center, New York, NY
| | - KD Crew
- Columbia University Medical Center, New York, NY
| | - S Refice
- Columbia University Medical Center, New York, NY
| | - SM Feldman
- Columbia University Medical Center, New York, NY
| | - B Taback
- Columbia University Medical Center, New York, NY
| | - H Hibshoosh
- Columbia University Medical Center, New York, NY
| | - T Su
- Columbia University Medical Center, New York, NY
| | - MM Maurer
- Columbia University Medical Center, New York, NY
| | - DL Hershman
- Columbia University Medical Center, New York, NY
| |
Collapse
|
33
|
Crew KD, Sivasubramanian PS, Aguirre AN, Smalletz C, Ngan MC, Xiao T, Kukafka R. Abstract P1-11-02: Identifying women at high-risk for breast cancer in the primary care setting. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p1-11-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast cancer risk assessment and available interventions for prevention, such as chemoprevention, are underutilized in the U.S. Reasons for low uptake include inability to routinely identify high-risk women in the primary care setting, inadequate time for counseling, and insufficient knowledge about risk-reducing strategies among primary care providers (PCPs) and patients. Our goal is to expand breast cancer risk counseling to a broader population of high-risk women identified in the primary care setting by developing a novel breast cancer risk navigation (BNAV) tool integrated into the electronic health record (EHR).
Methods: We propose to design the BNAV tool for PCPs, by integrating the Gail breast cancer risk assessment tool into the EHR. Our goal is to facilitate clinic workflow for the identification of high-risk women (5-year risk ≥1.7% or lifetime risk ≥20%), who may be referred for specialized risk counseling. We conducted recorded focus groups and individual interviews of PCPs (N = 20-25) at Columbia University Medical Center (CUMC), including internists, family practitioners, and gynecologists who use an EHR and see female patients, age 40-70 years, in the outpatient setting. We performed user analyses of PCPs on the characteristics of their practice and their clinic workflow. Information about the aims of BNAV and the development process were provided and PCPs were given an opportunity to ask questions and discuss the relative merits of BNAV and its potential application to clinical practice. Providers also completed a questionnaire to provide quantitative and qualitative feedback on BNAV. Verbal and written qualitative responses were condensed into themes using a qualitative approach based on grounded theory.
Results: In terms of breast cancer risk assessment, few providers routinely assessed for breast cancer risk factors apart from family history. Although some were familiar with the Gail model, no one used the risk calculator in their practice. Many PCPs were concerned about the added burden of incorporating the Gail model into the clinic visit. Potential solutions included screening for high-risk women during mammography and having patients complete the Gail model while in the waiting rooms. Most PCPs preferred referring high-risk women for specialized risk counseling, rather than directly discussing chemoprevention with their patients. Results from our interviews informed the selection of electronic resources to configure the BNAV tool. Using an open application programming interface within the EHR, the BNAV tool will incorporate the following approaches to workflow integration: 1) external decision support plug-ins for risk calculation; 2) dashboards with informatics-enabled summaries of patient history and breast cancer risk factors; 3) extracting data already available in the EHR for the Gail model breast cancer risk calculation; 4) alerts indicating high-risk patients should be referred for specialized risk counseling; 5) semi-structured referral orders for high-risk consultations.
Discussion: PCPs are on the front lines of preventive medicine and initiating the appropriate high-risk referrals. We propose to use health information technology methods to overcome barriers to breast cancer chemoprevention in the primary care setting.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-11-02.
Collapse
Affiliation(s)
- KD Crew
- Columbia University Medical Center, New York, NY
| | | | - AN Aguirre
- Columbia University Medical Center, New York, NY
| | - C Smalletz
- Columbia University Medical Center, New York, NY
| | - MC Ngan
- Columbia University Medical Center, New York, NY
| | - T Xiao
- Columbia University Medical Center, New York, NY
| | - R Kukafka
- Columbia University Medical Center, New York, NY
| |
Collapse
|
34
|
Shao T, Shane ES, McMahon D, Crew KD, Kalinsky K, Maurer M, Brown M, Gralow JR, Hershman DL. Abstract P6-12-03: Effects of high dose of bisphosphonate therapy on bone microarchitecture of the peripheral skeleton in women with early stage breast cancer. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p6-12-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Randomized studies investigating adjuvant bisphosphonates in women with breast cancer are ongoing. While bisphosphonates would be expected to prevent the deterioration of bone microarchitecture that accompanies hormone or chemotherapy, complete suppression of osteoclast activity for prolonged periods of time can decrease repair of micro-cracks, and possibly lead to decreased bone strength. While bone strength is governed by the amount of bone present, trabecular and cortical components of bone microarchitecture also contribute independently to bone strength. We aimed to characterize the effects of long-term bisphosphonates on bone microarchitecture in women with breast cancer using high-resolution peripheral quantitative computed tomography (HR-pQCT) of the distal radius and tibia.
Methods: We conducted a cross-sectional study involving early stage breast cancer patients treated with bisphosphonates on the S0307 clinical trial. Women were randomized to receive zoledronic acid, oral clodronate or oral ibandronate in doses far higher than those used in osteoporosis treatment as per protocol. After 18–36 months of bisphosphonate therapy, participates underwent a one-time evaluation of areal bone mineral density (aBMD) of the 1/3 radius, lumbar spine, and hip by dual energy x-ray absorptiometry (DXA), and cortical and trabecular volumetric BMD (vBMD) and trabecular microarchitecture of the radius and tibia by HR-pQCT. HR-pQCT measurements were compared to healthy young premenopausal women and age-matched Caucasian women.
Results: Baseline characteristics of the 12 enrolled patients: median age of 53 (range 40–67); white/Hispanics 7/5; pre/postmenopausal 4/8; mean body mass index 28.7 kg/m2 (20.9–34.8); average time on bisphosphonates 20 months (18–30); zoledronic acid/clodronate/ibandronate 5/6/1. The median aBMD DXA T-score of the 1/3 radius, lumbar spine and total hip were normal at +0.3, +0.1, and +0.2, respectively. Mean total, cortical, and trabecular vBMD of the radius as measured by HR-pQCT were 330±71, 905±55, and 146±35 mg hydroxyapatite/cm3, respectively. Mean cortical thickness was 0.803±0.170 mm, and mean trabecular number was 1.9±0.2. Mean total, cortical, and trabecular vBMD of the tibia were 285±54, 880±54, and 150±38 mg hydroxyapatite/cm3, respectively. Mean cortical thickness was 1.135±0.264 mm, and mean trabecular number was 1.7±0.3. There were no statistically significant differences between study group and each control. However, results were more similar to healthy young premenopausal control than the age-matched control.
Conclusion: Women on long-term bisphosphonate therapy for breast cancer had normal aBMD by DXA and normal cortical and trabecular vBMD, cortical thickness and trabecular number at the peripheral skeleton compared to healthy young women and age-matched women. This preliminary data is reassuring for cancer survivors if benefits from this therapy are established in the adjuvant setting.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-12-03.
Collapse
Affiliation(s)
- T Shao
- Beth Israel Medical Center, Continuum Cancer Centers of New York, New York, NY; Columbia University Medical Center, New York, NY; University of Washington/Seattle Cancer Care Alliance, Seattle, WA
| | - ES Shane
- Beth Israel Medical Center, Continuum Cancer Centers of New York, New York, NY; Columbia University Medical Center, New York, NY; University of Washington/Seattle Cancer Care Alliance, Seattle, WA
| | - D McMahon
- Beth Israel Medical Center, Continuum Cancer Centers of New York, New York, NY; Columbia University Medical Center, New York, NY; University of Washington/Seattle Cancer Care Alliance, Seattle, WA
| | - KD Crew
- Beth Israel Medical Center, Continuum Cancer Centers of New York, New York, NY; Columbia University Medical Center, New York, NY; University of Washington/Seattle Cancer Care Alliance, Seattle, WA
| | - K Kalinsky
- Beth Israel Medical Center, Continuum Cancer Centers of New York, New York, NY; Columbia University Medical Center, New York, NY; University of Washington/Seattle Cancer Care Alliance, Seattle, WA
| | - M Maurer
- Beth Israel Medical Center, Continuum Cancer Centers of New York, New York, NY; Columbia University Medical Center, New York, NY; University of Washington/Seattle Cancer Care Alliance, Seattle, WA
| | - M Brown
- Beth Israel Medical Center, Continuum Cancer Centers of New York, New York, NY; Columbia University Medical Center, New York, NY; University of Washington/Seattle Cancer Care Alliance, Seattle, WA
| | - JR Gralow
- Beth Israel Medical Center, Continuum Cancer Centers of New York, New York, NY; Columbia University Medical Center, New York, NY; University of Washington/Seattle Cancer Care Alliance, Seattle, WA
| | - DL Hershman
- Beth Israel Medical Center, Continuum Cancer Centers of New York, New York, NY; Columbia University Medical Center, New York, NY; University of Washington/Seattle Cancer Care Alliance, Seattle, WA
| |
Collapse
|
35
|
Hershman DL, Greenlee H, Awad D, Kalinsky K, Maurer M, Kranwinkel G, Brooks-Brafman L, Fuentes D, Tsai WY, Crew KD. Abstract P2-11-03: Randomized, single blind trial comparing limited and intensive survivorship interventions following adjuvant therapy in a multiethnic cohort of breast cancer survivors. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p2-11-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In 2005, the Institute of Medicine released a report citing the importance of comprehensive treatment summaries or “survivorship plans” for cancer patients completing adjuvant therapy. However, little is known about the best approach or the impact of these interventions on patient well-being. We compared quality of life, treatment satisfaction and cancer impact measures between a minimal or more intensive intervention.
Methods: The study was conducted at a single-institution academic breast cancer practice. Women with non-metastatic breast cancer were randomized within six weeks of completing adjuvant therapy (chemotherapy/radiation therapy) to a minimal intervention group (MG) or intensive intervention group (IG). The MG group was given the NCI publication, “Facing Forward: Life after Cancer Treatment” by lay research staff. The intensive group received the same NCI publication; met in person for 1 hour with a nurse practitioner who provided a treatment summary, surveillance and screening recommendations, and information on risk for late effects; and met in person for 1 hour with a nutritionist to review lifestyle recommendations. Subjects were informed that they were in a study of cancer survivors but unaware they were being randomized. The randomization was stratified by ethnicity (Hispanic/non-Hispanic). Both groups completed the 81-item impact of cancer instrument (IOC), functional assessment of chronic illness therapy-treatment satisfaction-patient satisfaction questionnaire (FACIT-TS-PS) and assessment of survivor concerns (AOC) at baseline, 3 and 6 months. Group t-tests and between group linear regression analyses were performed controlling for ethnicity.
Results: Of 140 patients who signed consent, 126 women (66 non-Hispanic, 60 Hispanic) completed baseline questionnaires, 109 completed 3 month, and 109 completed 6 month assessments. The groups were well balanced with regard to age (mean = 54), race, marital status, income and employment status. There were no statistically significant differences between the MG and IG on the 8 domains that comprise the FACIT-TS-PS at 3 and 6 months. The health worry scale of the AOC was lower in the IG (p = 0.006) compared to MG, indicating less health worry and the negative outlook score of the IOC was higher in the MG (p = 0.043) compared to IG at 3 months. At baseline, 3 and 6 months, Hispanic women compared to non-Hispanic women had significantly higher (worse) ACS and IOC health worry (p < 0.001), social life interference (p = 0.01) and meaning of cancer scales (p = 0.0004), but also had greater trust in medical professionals (p = 0.029).
Conclusions: We did not observe a difference in most of the IOC or treatment satisfaction scores between the MG and IG interventions at 3 or 6 months, nor did we find any significant change from baseline in either group. However, less health worry and less negative outlook were seen in the IG compared to the MG. At baseline and follow-up, Hispanic women in both interventions compared to non-Hispanic women had more extreme scores on most measures. Despite minimal difference between the interventions, the intensive intervention was more time-consuming and used more health care resources.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-11-03.
Collapse
Affiliation(s)
- DL Hershman
- Columbia Univeristy Medical Center, New York, NY; Mailman School of Public Health, New York, NY
| | - H Greenlee
- Columbia Univeristy Medical Center, New York, NY; Mailman School of Public Health, New York, NY
| | - D Awad
- Columbia Univeristy Medical Center, New York, NY; Mailman School of Public Health, New York, NY
| | - K Kalinsky
- Columbia Univeristy Medical Center, New York, NY; Mailman School of Public Health, New York, NY
| | - M Maurer
- Columbia Univeristy Medical Center, New York, NY; Mailman School of Public Health, New York, NY
| | - G Kranwinkel
- Columbia Univeristy Medical Center, New York, NY; Mailman School of Public Health, New York, NY
| | - L Brooks-Brafman
- Columbia Univeristy Medical Center, New York, NY; Mailman School of Public Health, New York, NY
| | - D Fuentes
- Columbia Univeristy Medical Center, New York, NY; Mailman School of Public Health, New York, NY
| | - W-Y Tsai
- Columbia Univeristy Medical Center, New York, NY; Mailman School of Public Health, New York, NY
| | - KD Crew
- Columbia Univeristy Medical Center, New York, NY; Mailman School of Public Health, New York, NY
| |
Collapse
|
36
|
Sivasubramanian PS, Hershman DL, Maurer M, Kalinsky K, Feldman S, Brafman L, Refice S, Kranwinkle G, Crew KD. Abstract P1-09-02: Pilot study of a 1-year intervention of high-dose vitamin D in women at high risk for breast cancer. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p1-09-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Selective estrogen receptor modulators (SERMs) have been shown to decrease breast cancer incidence among high-risk women, but uptake for prevention has been poor. Observational studies have demonstrated that serum 25-hydroxyvitamin D (25-OHD) is inversely related to breast cancer risk, such that levels >40 ng/ml are associated with about a 40% reduction in breast cancer risk compared to women who are vitamin D deficient (25-OHD <20 ng/ml). Uncertainty remains about whether vitamin D supplementation will reduce breast cancer risk, the optimal dose of vitamin D, and the target level of serum 25-OHD. We examined the safety of high dose vitamin D and the effects on serum 25-OHD in women at high risk for breast cancer.
Methods: Forty high-risk women (defined as a 5-year Gail risk ³1.67%, lobular or ductal carcinoma in situ [LCIS/DCIS], BRCA1/BRCA2 mutation carrier, or stage I/II invasive breast cancer in remission for >5 years) were assigned to a 1-year intervention of vitamin D3 20,000 or 30,000 IU weekly. Other eligibility criteria included baseline mammographic density (MD) ≥25%, serum 25-OHD ≤32 ng/ml, no current SERM use and no history of kidney stones. Women underwent a digital mammogram at baseline and 12 months, and serial blood draws every 3 months. In addition, random core breast biopsies were conducted in premenopausal women, whereas postmenopausal women underwent a breast MRI at baseline and 12 months. Participants were monitored for toxicity, particularly hypercalcemia and hypercalciuria, every 3 months. The primary objective is to determine the safety and feasibility of high-dose vitamin D in this study population. Secondary objectives are to determine changes in breast density and blood-based biomarkers (25-OHD, 1,25(OH)D, PTH, IGF-I, IGFBP-3). Serum 25-OHD was measured by Diasorin radioimmunoassay.
Results: From November 2007 to January 2011, 292 women were screened and 142 were ineligible. Main reasons for ineligibility (%) included 25-OHD >32 ng/ml (27), opted for SERM (23), prior kidney stones (11), and MD <25% (9). Of the 40 enrolled participants: median age 50 years (range, 37–73); pre/postmenopausal: 20/20; white/hispanic/black/asian: 19/14/6/1; median body mass index 26.6 kg/m2 (20–39.6); elevated Gail risk/LCIS/DCIS/stage I or II breast cancer: 20/10/8/2; mean baseline serum 25-OHD 20.2 ng/ml (9–31). Currently, 1 participant is on-study, 31 completed the intervention, 6 were lost to follow-up, 1 withdrew due to hypercalciuria (spot urine Ca/Cr >0.37) and 1 withdrew due to dyspepsia. Mean serum 25-OHD rose to 47 ng/ml at 3 months, 49.1 ng/ml at 6 months, and 53.7 ng/ml (range, 26–77) at 12 months. No significant hypercalcemia (serum Ca >10.5 mg/dl) occurred at either dose level. Imaging and biomarker analyses are ongoing.
Discussion: We have demonstrated that a 1-year intervention of high-dose vitamin D3 is well tolerated and can increase serum 25-OHD above a target level of 40 ng/ml. This preliminary data has informed an ongoing phase IIb randomized placebo-controlled trial (SWOG 0812) of high-dose vitamin D in 200 high-risk premenopausal women and highlights the importance of early phase breast cancer chemoprevention trials with intermediate biomarker endpoints to test novel agents.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-09-02.
Collapse
Affiliation(s)
| | | | - M Maurer
- Columbia University, New York, NY
| | | | | | | | - S Refice
- Columbia University, New York, NY
| | | | - KD Crew
- Columbia University, New York, NY
| |
Collapse
|
37
|
Kalinsky K, Crew KD, Refice S, Wang A, Feldman SM, Taback B, Hibshoosh H, Maurer M, Hershman DL. Abstract PD03-03: Pre-surgical Trial of Metformin in Overweight and Obese, Multi-ethnic Patients with Newly Diagnosed Breast Cancer. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-pd03-03] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Overweight or obese women with breast cancer (BC) have a higher risk of distant recurrence and death compared to normal weight women. There is increasing evidence that insulin significantly mediates these adverse clinical outcomes. Laboratory and population studies demonstrate that metformin offers a protective BC effect through reduction of serum insulin levels and direct modulation of cellular protein synthesis and growth through AMPK pathway signaling. Our aim is to assess the biologic impact of metformin on blood- and tumor-based markers on insulin, IGF and AMPK/mTOR pathway signaling, and/or proliferation in operable BC patients with a body mass index (BMI) ≥ 25 kg/m2.
Methods: The study was an open-label pre-surgical trial with metformin 1500 mg PO per day (500 mg am/1000 mg pm) for 2–4 weeks prior to surgical resection in 35 overweight or obese patients with invasive BC (n = 25) or ductal carcinoma in situ (n = 10) and no history of diabetes. The primary endpoint was to assess a reduction in tumor proliferation. We have 80% power to detect a 30% decrease in Ki-67 in invasive BCs from baseline to post-metformin values (two-sample t-test, 0.05). Secondary endpoints include changes in BMI and insulin resistance markers, such as fasting serum insulin, lipid panel, glucose, leptin, and adiponectin. Tumor markers will be compared to untreated historical controls matched by age, BMI, and tumor characteristics.
Results: Between Oct 2009 to Aug 2011, we screened 116 patients, enrolling 35 with newly diagnosed BC: 18/34 overweight (27.6: 25.1–29.7) and 16/34 obese (35.9: 30.5–46.4). Hispanic women made up 80% of the population (28/35). The median metformin duration was 22 days (1–64). All took metformin until the evening prior to surgery, except 2 (1 withdrew and 1 stopped early after surgery delay). More than half had a prior diagnosis of hypertension and a third had hypercholesterolemia. In the invasive BC cohort (n = 25), 19/25 (76%) were HR+/HER2−. The most common grade I-II included self-limiting diarrhea, flatulence, abdominal pain, fatigue, and anorexia. Grade III events included abdominal pain (n = 1) and diarrhea (n = 3). The change in blood markers are described in the table. Tumor Ki-67 (immunohistochemistry) and pathway signaling analyses (reverse protein microarray) are ongoing.
Conclusions: Our study is unique to other pre-surgical metformin trials due to the enrichment of overweight/obese BC patients and the ethnically diverse population. We observed a significant decrease in serum cholesterol and leptin with metformin, and a trend toward lower insulin, HOMA, and adiponectin. No significant changes in glucose or IGFP-3 levels are noted. We are awaiting tumor-based biomarker evaluation. Pre-surgical trials can assess an agent's biological effect prior to long-term intervention trials.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr PD03-03.
Collapse
Affiliation(s)
- K Kalinsky
- Columbia University Medical Center, New York, NY
| | - KD Crew
- Columbia University Medical Center, New York, NY
| | - S Refice
- Columbia University Medical Center, New York, NY
| | - A Wang
- Columbia University Medical Center, New York, NY
| | - SM Feldman
- Columbia University Medical Center, New York, NY
| | - B Taback
- Columbia University Medical Center, New York, NY
| | - H Hibshoosh
- Columbia University Medical Center, New York, NY
| | - M Maurer
- Columbia University Medical Center, New York, NY
| | - DL Hershman
- Columbia University Medical Center, New York, NY
| |
Collapse
|
38
|
Reimers LL, Campbell J, Hershman D, Greenlee H, Terry MB, Maurer M, Kalinsky K, Jayasena R, Sandoval R, Alvarez M, Crew KD. P4-11-06: Uptake of Selective Estrogen Receptor Modulators and Other Breast Cancer Prevention Strategies among High-Risk Women Seen in a Breast Center. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p4-11-06] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Selective estrogen receptor modulators (SERMs), tamoxifen and raloxifene, are FDA-approved for breast cancer (BC) risk reduction. However, uptake has been poor in the prevention setting, partly due to a lack of knowledge in the medical community about BC prevention and public misconceptions about the risks of SERMs. We assessed demographic and clinical factors that influence SERM uptake among high-risk women seen in an academic breast center, where specialized risk counseling is provided by a breast surgeon or medical oncologist.
Methods: Potential subjects included high-risk women seen for an initial consultation by Breast Surgery or Medical Oncology. Eligibility for SERM use included a 5-year Gail risk ≥1.67%, lobular carcinoma in situ (LCIS), BRCA mutation carrier, or estrogen receptor (ER)-positive and/or progesterone receptor (PR)-positive ductal carcinoma in situ (DCIS). Demographic and BC risk factor data was collected from self-administered questionnaires. Clinical data, including prior/current SERM use, was abstracted from medical chart review. Differences in distribution of risk factors, between women who ever took a SERM and those who did not, were examined using chi-square statistics or Fisher's exact test. Multivariable logistic regression models were used to calculate odds ratios (OR) and 95% confidence intervals using SERM use as the dependent variable.
Results: Among 247 high-risk women enrolled between March 2007 and January 2011, median age 51 (17-82); White/Hispanic/Black/Asian (%): 55/32/7/6. 85% of women were undergoing annual mammography, 94% had a breast biopsy, 19% genetic testing, and 71% Medical Oncology referral. Among 181 (73%) women eligible for a SERM, Gail risk ≥1.67%/LCIS/DCIS/BRCA mutation (%): 35/22/39/3; 83 (46%) ever took a SERM, including 62 on tamoxifen and 21 on raloxifene. Early SERM discontinuation was only 7%. In multivariable analysis, significant predictors of SERM uptake included risk category (DCIS vs. Gail risk ≥1.67%/LCIS/BRCA mutation), higher income, higher body mass index (BMI), and referral to Medical Oncology. In terms of this high-risk population meeting American Cancer Society (ACS) behavioral guidelines for cancer prevention, 53% had a BMI <25 kg/m2, 44% consumed ≤1 alcoholic beverage per day, and 10% engaged in ≥4 hours of moderate physical activity per week; only 3.5% met all 3 recommendations.
Conclusions: Among high-risk women seen at a specialized breast center, application of clinical recommendations such as screening mammography, genetic testing, and SERM uptake were relatively high, suggesting that a comprehensive approach to the management of high-risk women is feasible. However, meeting ACS nutrition and physical activity guidelines for cancer prevention was limited, perhaps due to a lack of reimbursable staff to implement these guidelines. Breast cancer risk assessment and available interventions for prevention among high-risk women are underutilized in the U.S. Future studies should focus on the development and delivery of breast cancer prevention strategies.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-11-06.
Collapse
Affiliation(s)
- LL Reimers
- 1Columbia University Mailman School of Public Health, New York, NY; Columbia University College of Physicians and Surgeons, New York, NY; Columbia University, New York, NY
| | - J Campbell
- 1Columbia University Mailman School of Public Health, New York, NY; Columbia University College of Physicians and Surgeons, New York, NY; Columbia University, New York, NY
| | - D Hershman
- 1Columbia University Mailman School of Public Health, New York, NY; Columbia University College of Physicians and Surgeons, New York, NY; Columbia University, New York, NY
| | - H Greenlee
- 1Columbia University Mailman School of Public Health, New York, NY; Columbia University College of Physicians and Surgeons, New York, NY; Columbia University, New York, NY
| | - MB Terry
- 1Columbia University Mailman School of Public Health, New York, NY; Columbia University College of Physicians and Surgeons, New York, NY; Columbia University, New York, NY
| | - M Maurer
- 1Columbia University Mailman School of Public Health, New York, NY; Columbia University College of Physicians and Surgeons, New York, NY; Columbia University, New York, NY
| | - K Kalinsky
- 1Columbia University Mailman School of Public Health, New York, NY; Columbia University College of Physicians and Surgeons, New York, NY; Columbia University, New York, NY
| | - R Jayasena
- 1Columbia University Mailman School of Public Health, New York, NY; Columbia University College of Physicians and Surgeons, New York, NY; Columbia University, New York, NY
| | - R Sandoval
- 1Columbia University Mailman School of Public Health, New York, NY; Columbia University College of Physicians and Surgeons, New York, NY; Columbia University, New York, NY
| | - M Alvarez
- 1Columbia University Mailman School of Public Health, New York, NY; Columbia University College of Physicians and Surgeons, New York, NY; Columbia University, New York, NY
| | - KD Crew
- 1Columbia University Mailman School of Public Health, New York, NY; Columbia University College of Physicians and Surgeons, New York, NY; Columbia University, New York, NY
| |
Collapse
|
39
|
Hershman DL, Unger JM, Crew KD, Moinpour CM, Minasian LM, Hansen L, Lew DL, Kaberle K, Wade JL, Meyskens FL. OT2-07-02: SWOG S0927: A Randomized Double Blind Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor (AI)-Induced Musculoskeletal Pain in Women with Early Stage Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-ot2-07-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Despite the well-proven efficacy of aromatase inhibitors(AIs) for the treatment of hormone-sensitive breast cancer, a significant number of women suffer from musculoskeletal side-effects which can result in early discontinuation of this important medication. Given the proposed anti-inflammatory effects of omega-3-fatty acid and the paucity of therapeutic options for AI-induced arthralgia, it is therefore reasonable to test the efficacy of omega-3-fatty acid in women with breast cancer who have developed moderate to severe joint symptoms after initiating AIs.
Specific aims: To assess if omega-3-fatty acid as compared to placebo causes a reduction in worst joint pain/stiffness in women with AI-associated arthralgias at 12weeks as measured by the modified Brief Pain Inventory (BPI). Additional measures will include the WOMAC, M-SACRAH, FACT-ES and global rating of change, which will be assessed at baseline, 6, 12 and 24 weeks. We will evaluate fasting lipids, hormone levels, serum inflammatory markers (TNF, IL2, CRP), and markers of joint destruction (CTX-II) at baseline, 12 and 24 weeks.
Eligibility criteria:Pts. must have histologically-confirmed stages I-III breast cancer, with no evidence of metastatic disease and undergone definitive breast cancer surgery. Pts must be post-menopausal and currently be taking a third-generation AI —anastrazole(Arimidex®), letrozole (Femara®), or exemestane (Aromasin®) for at least the previous 90 days prior to registration with plans to continue for at least an additional 180 days after registration.The patient must have a worse joint pain/stiffness score of 5 or greater on the 10-point scale of the BPI which started or increased after initiation of AI. Pts must not have taken omega-3-fatty acid supplements within the past 3 months prior to registration.Pts will be randomized to receive 6 capsules daily (at 1,000 mg each; ∼600mg combination of ethyl esters EPA/DHA) of omega-3-fattyacid or matching placebo daily for 24 weeks. Statistical methods:We stipulate an alpha=.05 two-sided test, with an estimated 5% non-adherenceand 20% dropout rate at the primary endpoint evaluation time of 12 weeks after randomization. For a two point difference in worst joint pain/stiffness and a 3.5 point SD at 12 weeks, 222 eligible patients would be required for 90% power under a two-arm normal design. To allow ineligibility rate of 10%, 246 total pts will be enrolled. The study should be activated September 2011. Funding: Supported by National Cancer Institute grant CA037429
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr OT2-07-02.
Collapse
Affiliation(s)
- DL Hershman
- 1Columbia University, New York, NY; SWOG, Seattle, WA; National Cancer Institute, Bethesda, MD; Legacy Good Samaritan Hosp & MC, Portland, OR; SWOG, San Antonio, TX; Cancer Care Specialists of Illinois, Decatur, IL; University of California, Irvine, Orange County, CA
| | - JM Unger
- 1Columbia University, New York, NY; SWOG, Seattle, WA; National Cancer Institute, Bethesda, MD; Legacy Good Samaritan Hosp & MC, Portland, OR; SWOG, San Antonio, TX; Cancer Care Specialists of Illinois, Decatur, IL; University of California, Irvine, Orange County, CA
| | - KD Crew
- 1Columbia University, New York, NY; SWOG, Seattle, WA; National Cancer Institute, Bethesda, MD; Legacy Good Samaritan Hosp & MC, Portland, OR; SWOG, San Antonio, TX; Cancer Care Specialists of Illinois, Decatur, IL; University of California, Irvine, Orange County, CA
| | - CM Moinpour
- 1Columbia University, New York, NY; SWOG, Seattle, WA; National Cancer Institute, Bethesda, MD; Legacy Good Samaritan Hosp & MC, Portland, OR; SWOG, San Antonio, TX; Cancer Care Specialists of Illinois, Decatur, IL; University of California, Irvine, Orange County, CA
| | - LM Minasian
- 1Columbia University, New York, NY; SWOG, Seattle, WA; National Cancer Institute, Bethesda, MD; Legacy Good Samaritan Hosp & MC, Portland, OR; SWOG, San Antonio, TX; Cancer Care Specialists of Illinois, Decatur, IL; University of California, Irvine, Orange County, CA
| | - L Hansen
- 1Columbia University, New York, NY; SWOG, Seattle, WA; National Cancer Institute, Bethesda, MD; Legacy Good Samaritan Hosp & MC, Portland, OR; SWOG, San Antonio, TX; Cancer Care Specialists of Illinois, Decatur, IL; University of California, Irvine, Orange County, CA
| | - DL Lew
- 1Columbia University, New York, NY; SWOG, Seattle, WA; National Cancer Institute, Bethesda, MD; Legacy Good Samaritan Hosp & MC, Portland, OR; SWOG, San Antonio, TX; Cancer Care Specialists of Illinois, Decatur, IL; University of California, Irvine, Orange County, CA
| | - K Kaberle
- 1Columbia University, New York, NY; SWOG, Seattle, WA; National Cancer Institute, Bethesda, MD; Legacy Good Samaritan Hosp & MC, Portland, OR; SWOG, San Antonio, TX; Cancer Care Specialists of Illinois, Decatur, IL; University of California, Irvine, Orange County, CA
| | - JL Wade
- 1Columbia University, New York, NY; SWOG, Seattle, WA; National Cancer Institute, Bethesda, MD; Legacy Good Samaritan Hosp & MC, Portland, OR; SWOG, San Antonio, TX; Cancer Care Specialists of Illinois, Decatur, IL; University of California, Irvine, Orange County, CA
| | - FL Meyskens
- 1Columbia University, New York, NY; SWOG, Seattle, WA; National Cancer Institute, Bethesda, MD; Legacy Good Samaritan Hosp & MC, Portland, OR; SWOG, San Antonio, TX; Cancer Care Specialists of Illinois, Decatur, IL; University of California, Irvine, Orange County, CA
| |
Collapse
|
40
|
Lim EA, Hershman DL, Greenlee H, Crew KD, Maurer MA, Hibshoosh H, Kalinsky K. P2-14-03: A Comparison of Biologic Differences in Tumors in a Matched Cohort of Hispanic and Caucasian Women with Early-Stage Breast Cancer Using the 21-Gene Recurrence Score Assay. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p2-14-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Several studies demonstrate that Hispanic women have a higher mortality rate and lower incidence of breast cancer (BC) as compared to Caucasian women. This survival pattern has also been observed in Hispanic women with untreated, early-stage BC. The Hispanic population should be considered a heterogeneous group, however, given the various racial and national backgrounds that comprise this entity. As African American (AA) similarly demonstrate a worse survival as compared to Caucasian women, a retrospective analysis of 27 tumor from AA patients (pts) showed a significantly higher expression of the 5 proliferation genes in the 21-gene recurrence score (RS) assay (Oncotype Dx) as compared to other races, with no significant difference observed in the 21-gene RS. The primary aim of this analysis is to investigate biologic differences between Hispanic women in a primarily Dominican Republic population, as compared to Caucasian women, as determined by indices in the 21-gene RS assay.
Methods: We collected data from women with early-stage breast cancer who underwent RS assay testing between 2005 and 2011. Pt charts were reviewed for ethnicity (Hispanic or other), country of origin, RS, 10-year risk of distant recurrence, and breast tumor ER/PR/HER2 expression by Oncotype Dx. Hispanic pts were matched to Caucasians in a 1:2 fashion based on age (+/− 10 years), tumor stage, and presence of lymph node metastases. Prognostically important clinicopathologic features were collected, including lymphovascular invasion (LVI) and grade. Descriptive statistics were computed. Two Sample t-testing was used to evaluate if RS was equal across by ethnicity groups.
Results: Of 214 pts who underwent RS testing, 30 (13.5%) were Hispanic: 18 from the Dominican Republic, 5 from Puerto Rico, and 1 from various Central and South American populations. The 30 Hispanic women were matched to 57 Caucasians: total population 87 pts. The mean RS for Caucasian women was 18.3 (range: 0–54) and for Caucasians: 15.5 (range: 1–38). By two Sample t test, no statistically different differences were observed between Hispanic and Caucasian women in regards to the RS (p= 0.2828) or 10-year distant recurrence score after 5 years of anti-estrogen therapy (p=0.4218). No differences were observed in median ER expression (9.4% vs. 10.1%: Hispanic vs. Caucasian), PR (7.2% vs. 7.7%), or HER2 (9.2% vs. 9.0%). LVI was numerically more frequently identified in Hispanic pts [7/30 (23.3%) vs. 8/57 (14.0%)], as were grade III tumors [7/30 (23.3%) and 4/57 (7%)].
Conclusions: Similar to the findings with AA pts, there was no significant difference in RS between Hispanic and matched Caucasian women with early-stage BCs. A numerical trend to a higher RS was seen in this Hispanic population of primarily pts from the Dominican Republic. We will evaluate for differences in the 5 genes involved in proliferation (CCNB1, MKI17, MYBL2, BIRC5, AURKA). Also, further analyses will be conducted with additional pts to determine if the numeric differences in RS, LVI, and grade are observed in a larger cohort.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-14-03.
Collapse
Affiliation(s)
- EA Lim
- 1Columbia University Medical Center, New York, NY; Mailman School of Public Health, New York, NY
| | - DL Hershman
- 1Columbia University Medical Center, New York, NY; Mailman School of Public Health, New York, NY
| | - H Greenlee
- 1Columbia University Medical Center, New York, NY; Mailman School of Public Health, New York, NY
| | - KD Crew
- 1Columbia University Medical Center, New York, NY; Mailman School of Public Health, New York, NY
| | - MA Maurer
- 1Columbia University Medical Center, New York, NY; Mailman School of Public Health, New York, NY
| | - H Hibshoosh
- 1Columbia University Medical Center, New York, NY; Mailman School of Public Health, New York, NY
| | - K Kalinsky
- 1Columbia University Medical Center, New York, NY; Mailman School of Public Health, New York, NY
| |
Collapse
|
41
|
Kalinsky K, Sparano JA, Kim M, Crew KD, Maurer MA, Taback B, Feldman SM, Hibshoosh H, Wiechmann L, Adelson KB, Hershman DL. Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps147] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
42
|
Greenlee H, Crew KD, Shao T, Kranwinkel G, Brafman L, Kalinsky K, Maurer M, Tsai WY, Hershman DL. Abstract P2-13-02: Phase II Study of Glucosamine with Chondroitin on Joint Symptoms Induced by Aromatase Inhibitors in Breast Cancer Patients. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p2-13-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Aromatase inhibitors (AIs) are commonly used as adjuvant endocrine therapy in postmenopausal women with hormone receptor-positive breast cancer (BC). However, many patients treated with AIs experience joint symptoms which may lead to non-adherence to treatment. We examined whether glucosamine plus chondroitin improves AI-induced arthralgias in women with early stage BC.
Methods: This is a single-arm Phase II study evaluating the efficacy of glucosamine and chondroitin in postmenopausal BC patients with moderate to severe AI-induced arthralgias. Patients took glucosamine sulfate (1500mg/d) + chondroitin sulfate (1200mg/d) for 24 weeks, and were assessed every 6 weeks. The primary endpoint was change in Outcome Measure in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) criteria at 24 weeks. Secondary endpoints include changes in Brief Pain/Stiffness Inventory-Short Form (BPI-SF), Western Ontario and McMaster Universities Osteoarthritis (WOMAC), Modified Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands (M-SACRAH), quality of life, grip strength and estradiol level. A Simon two-stage design was used. If 7/22 responses were observed, the trial would continue. Results: Of 36/46 patients enrolled to date, 21 were evaluable at 24 weeks. Median age: 61 (46-80); White/Hispanic/Black/Asian: 11/5/4/1. At 24 weeks, 12/21 patients (57%) had improved pain/stiffness or function in their knees or hips, and 14/21 patients (67%) had improvement in their hands, and 80% had improvement in hands and/or knees. There were also decreases in BPI pain/stiffness severity and functional interference (P<0.05). Reassuringly, there was no increase in serum estradiol levels. Conclusion: Glucosamine and chondroitin is a well-tolerated and potentially effective treatment for AI-induced arthralgia. Evaluation of these agents in a placebo controlled phase III study is warranted.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-13-02.
Collapse
Affiliation(s)
- H Greenlee
- Columbia University Medical Center, New York, NY; Mailman School of Public Health, New York, NY
| | - KD Crew
- Columbia University Medical Center, New York, NY; Mailman School of Public Health, New York, NY
| | - T Shao
- Columbia University Medical Center, New York, NY; Mailman School of Public Health, New York, NY
| | - G Kranwinkel
- Columbia University Medical Center, New York, NY; Mailman School of Public Health, New York, NY
| | - L Brafman
- Columbia University Medical Center, New York, NY; Mailman School of Public Health, New York, NY
| | - K Kalinsky
- Columbia University Medical Center, New York, NY; Mailman School of Public Health, New York, NY
| | - M Maurer
- Columbia University Medical Center, New York, NY; Mailman School of Public Health, New York, NY
| | - WY Tsai
- Columbia University Medical Center, New York, NY; Mailman School of Public Health, New York, NY
| | - DL. Hershman
- Columbia University Medical Center, New York, NY; Mailman School of Public Health, New York, NY
| |
Collapse
|
43
|
Kalinsky K, Crew KD, Feldman SM, Taback B, Joseph KAP, Hibshoosh H, Refice S, Maurer M, Hershman DL. Abstract P1-11-15: Improving Patient Accrual to “Window of Opportunity” Trials. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p1-11-15] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: A challenge in evaluating new targeted investigational agents is procuring tumor tissue to measure the direct biologic effect on tumor cells. Pre-surgical studies, i.e. “window of opportunity” trials, in women with newly diagnosed, operable breast cancer (BC) provide an opportunity to assess the biologic impact of new agents on human tissue. The study drug is taken between the time of diagnostic biopsy and definitive surgical resection (approx 2-4 weeks). Pre-and post-treatment blood and tumor tissue are collected to evaluate for biomarker modulation. While these trials are appealing, conducting them can be difficult. We present the evolution of a multidisciplinary pre-surgical program, focusing on “lessons learned” with regard to patient accrual, improving tissue acquisition, and maintaining quality control.
Material and Methods: We have completed 2 pre-surgical studies (anastrazole, polyphenon E), with 1ongoing (metformin).The Recruitment Core is a shared NCI cancer center resource that identifies and screens participants for active studies. Charts of women with newly diagnosed BC are screened for eligibility. If a patient is deemed appropriate by the surgeon, she is introduced to the recruiters, and the medical oncology research team evaluates the patient that day. Once consented, the patient undergoes blood collection and clinical evaluation prior to study drug usage (same day or next). The research staff contacts the patient by phone weekly to assess toxicities and ensure medication adherence. The patient presents the day of or prior to surgery for blood work and clinical examination. The post-treatment surgical resection tissue (paraffin embedded and frozen) is collected for biomarker analysis.
Results: We have enrolled 52 patients to 3 trials: 10 at a rate of 2.5/month, 25 at 1.5/month, and 17 at 2.5/month. Stress from the diagnosis and fear of toxicity are the main reasons for not enrolling. Another barrier to enrollment is strict eligibility criteria; for example,28/66 (43%) patients were ineligible due to a required BMI > 25 without known diabetes. The majority of patients are not overwhelmed by the trial discussion and appreciate the oncology consultation prior to surgery. Weekly multidisciplinary meetings have resulted in improvements to study accrual and data quality. Over time, the requirements for tumor acquisition have been standardized to decrease variability in biomarker analysis. To ensure sufficient quantity of pre-study tumor tissue, patients undergo up to 4 core biopsies at diagnosis (tumor>1cm). To limit the warm ischemia period and ensure biomarker reproducibility, core biopsies are fixed within 20 minutes. At resection, the surgical specimen is placed in ice-cold formalin within 30 minutes of devascularization. Excisions are fixed for 6-48 hours prior to processing.
Conclusion: Studying a new agent pre-surgically is an effective tool in assessing a drug's impact on tumor biology and predictive biomarkers. In order for pre-surgical studies to be successful, a close collaboration between radiology, surgery, medical oncology and pathology must be established and continually reassessed. We plan to utilize this multidisciplinary approach to successfully complete future pre-surgical studies, including a multicenter trial with a novel AKT inhibitor.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-11-15.
Collapse
Affiliation(s)
- K Kalinsky
- Columbia University Medical Center, New York, NY
| | - KD Crew
- Columbia University Medical Center, New York, NY
| | - SM Feldman
- Columbia University Medical Center, New York, NY
| | - B Taback
- Columbia University Medical Center, New York, NY
| | - K-AP Joseph
- Columbia University Medical Center, New York, NY
| | - H Hibshoosh
- Columbia University Medical Center, New York, NY
| | - S Refice
- Columbia University Medical Center, New York, NY
| | - M Maurer
- Columbia University Medical Center, New York, NY
| | - DL. Hershman
- Columbia University Medical Center, New York, NY
| |
Collapse
|
44
|
Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL, Vornik L, Cornelison TL, Hershman DL. Phase IB randomized, double-blinded, placebo-controlled, dose-escalation study of polyphenon E in women with a history of hormone receptor-negative breast cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.tps142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Hershman DL, McMahon D, Crew KD, Shao T, Cremers S, Brafman L, Awad D, Shane E. Evaluation of the protective effects of zoledronic acid on bone mass in premenopausal women undergoing adjuvant chemotherapy following treatment discontinuation. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
562 Background: Adjuvant chemotherapy is associated with a significant reduction in bone mineral density (BMD) in premenopausal women with breast cancer (BC). We previously showed that this loss of BMD can be prevented with zoledronic acid (ZA) every 3 months for a year. Since bone loss in women with osteoporosis is prevented with annual ZA, we examined whether protection from bone loss by ZA in women with BC persists following discontinuation of ZA. Methods: A randomized, double-blind, multicenter, phase III trial comparing ZA (4 mg every 3 months) versus placebo for 1 year in premenopausal women with BC undergoing adjuvant chemotherapy was conducted. Patients had serial BMD measurement at 0 (after surgery and before chemotherapy), 6, 12 and 24 months. Demographic, clinical, and tumor characteristics were collected. Serum was stored at -70°C and analyzed in batches. The secondary outcome of percent change in BMD at 24 months, one year following the last ZA/placebo, is presented. Intention-to-treat analyses with linear mixed models were performed using SAS version 9. Results: Of 101 patients randomized, 85 completed 12 month, and 62 completed 24 month evaluations; mean age 41 (SD 5.2). Demographic and baseline characteristics were similar between treatment groups. By 24 months, 38 (61%) had not regained their menses; 22 patients were on tamoxifen, 25 were on an aromatase inhibitor. Chemotherapy without ZA was associated with a significant decline from baseline in lumbar spine (LS) BMD after both 12 (-5.4%) and 24 (-6.3%) months. Similarly total hip (TH) and femoral neck (FN) BMD declined by 2.6% and 2.4% by 24 months, respectively. In contrast, BMD remained stable in ZA-treated patients (p < 0.0001 vs placebo). Patients who received ZA had stable BMD at 24 months (LS -0.58%, TH 0.83%, FN 0.04%). Analysis of bone turnover markers is ongoing. Conclusions: Premenopausal women receiving adjuvant chemotherapy for BC had significant bone loss in the first year that persisted in the second year. ZA every 3 months for a year effectively prevented bone loss during the first year and 1 year after completion of ZA treatment. One year of ZA maintains BMD in premenopausal BC patients for an additional year after discontinuation of ZA. [Table: see text]
Collapse
Affiliation(s)
| | - D. McMahon
- Columbia University Medical Center, New York, NY
| | - K. D. Crew
- Columbia University Medical Center, New York, NY
| | - T. Shao
- Columbia University Medical Center, New York, NY
| | - S. Cremers
- Columbia University Medical Center, New York, NY
| | - L. Brafman
- Columbia University Medical Center, New York, NY
| | - D. Awad
- Columbia University Medical Center, New York, NY
| | - E. Shane
- Columbia University Medical Center, New York, NY
| |
Collapse
|
46
|
Crew KD, Capodice J, Greenlee H, Brafman L, Fuentes D, Awad D, Hershman DL. Randomized, blinded, placebo-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.571] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
571 Background: Aromatase inhibitors (AIs) have become the standard of care for the treatment of postmenopausal, hormone-sensitive breast cancer (BC). However, patients receiving AIs may experience joint symptoms which can lead to early discontinuation of this effective therapy. We examined whether acupuncture improves AI-induced arthralgias in women with early stage BC. Methods: This study is a randomized, single-blinded trial of true vs sham acupuncture twice weekly for 6 weeks in postmenopuasal women with early stage BC and self-reported musculoskeletal pain related to adjuvant AI therapy. The active intervention included full body/auricular acupuncture and a joint-specific point prescription, whereas the sham arm involved superficial needle insertion at nonacupoint locations. Outcome measures included the Brief Pain Inventory-Short Form (BPI-SF), Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC), and Modified Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands (M-SACRAH) obtained at baseline, 3 and 6 weeks. Lower scores reflect improvement in symptoms. Results: Of 43 women enrolled, 38 were evaluable at 6 weeks. Baseline characteristics were comparable between the groups. Median age: 57 (37–77); White/Hispanic/Black/Asian: 15/21/1/1; median body mass index (kg/m2): 29 (18–45). True acupuncture was associated with about a 50% decrease in mean BPI-SF scores, whereas no change from baseline was observed for the sham acupuncture group (see table). Similar findings were seen for the WOMAC and M-SACRAH pain, stiffness, and function scores (P<0.05). No adverse events were reported. Conclusions: Women with AI-induced arthralgias treated with acupuncture had significant improvement of joint pain and stiffness, which was not seen with sham acupuncture. Acupuncture is an effective and well-tolerated strategy for managing this common treatment-related side effect. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | | | | | | | | | - D. Awad
- Columbia University, New York, NY
| | | |
Collapse
|
47
|
Crew KD, Zauderer MG, Cho C, Weimer LH, Brafman L, Fuentes D, Sierra A, Hershman DL. Prospective evaluation of neurotoxicity in breast cancer patients treated with adjuvant paclitaxel. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-1115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #1115
Background: Taxanes are increasingly used in the treatment of early stage breast cancer (BC). Up to 30% of patients develop moderate-severe neurotoxicity during treatment. We recently reported that about 60% of BC patients complain of some neuropathy up to 2 years after completing adjuvant paclitaxel (T) treatment. The prevalence, severity, and natural history of this syndrome have not been well described.
 Methods: Using a prospective cohort study design, women with stage I-III breast cancer undergoing adjuvant paclitaxel were enrolled. At baseline, 4 weeks, 8 weeks, 3 months, and 6 months, all patients completed the Functional Assessment of Cancer Therapy-Taxane (FACT-Tax) and quantitative sensory testing (touch perception and vibration threshold) was conducted. The FACT-Tax includes a 16-item subscale which measures the severity of neurotoxicity, where lower scores represent worsening symptoms. Blood was obtained at baseline and 2 weeks post-treatment to measure serum nerve growth factor (NGF) levels.
 Results: A total of 34 out of a target of 50 patients have been enrolled to date; median age: 48 (32-77); White/Hispanic/Black/Other: 10/17/4/1; median body mass index (kg/m2): 28 (21-44); stage I/II/III: 4/19/8; paclitaxel regimen T q2wks x4/T q2wks x6/T qwk x12: 19/8/5. Compared to baseline, there was a significant decrease in vibration sense at 8 weeks during active treatment. Mean scores on the Neurotoxicity subscale of the FACT-Tax decreased from 37.3 at baseline to 30.7 at week 4 (p=0.009) and 29.7 at week 8 (p=0.006). These scores remained lower than baseline at 3 months and 6 months after completing paclitaxel treatment (33.7 and 33.2, respectively). At 6 months, up to 50% of patients reported persistent numbness or discomfort in the hands and feet. Serum NGF analyses are underway to determine whether this biomarker correlates with neuropathy symptoms.
 Discussion: To our knowledge, this is one of the first studies to prospectively evaluate persistent neuropathy in women prior to, during and following adjuvant paclitaxel therapy. Over 50% of patients developed moderate to severe neuropathy during active treatment, which persisted 6 months post-treatment. Taxane-based chemotherapy has been shown to improve survival, however, neurotoxicity is the main long-term side effect. Understanding the natural history of this toxicity and validating appropriate measures to be used in interventions to prevent and treat taxane-induced neuropathy are critical.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1115.
Collapse
Affiliation(s)
- KD Crew
- 1 Medicine, Columbia University, New York, NY
- 2 Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY
| | - MG Zauderer
- 1 Medicine, Columbia University, New York, NY
| | - C Cho
- 1 Medicine, Columbia University, New York, NY
| | - LH Weimer
- 3 Neurology, Columbia University, New York, NY
| | - L Brafman
- 2 Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY
| | - D Fuentes
- 2 Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY
| | - A Sierra
- 2 Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY
| | - DL Hershman
- 1 Medicine, Columbia University, New York, NY
- 2 Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY
| |
Collapse
|
48
|
Yu B, Lobo R, Crew KD, Ferin MJ, Douglas N, Nakhuda GS, Hershman DL. Predictive markers of chemotherapy-induced menopause in premenopausal women under the age of 40 with breast cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-1118] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #1118
Background: Premenopausal women undergoing adjuvant chemotherapy are at risk for chemotherapy induced menopause (CIM). To date, age >40 has been the strongest predictor of ovarian failure. For women <40, identifying patients early who are at greatest risk may alter treatment decisions, therefore early predictors of CIM are needed. Our objective was to assess a marker of ovarian reserve, Mullarian Inhibitory Substance (MIS), as well as estradiol (E2), Follicle Stimulating Hormone (FSH) and menstrual status, in young women undergoing adjuvant chemotherapy for breast cancer.
 Patients and Methods: We conducted a prospective cohort study in women aged less than 40 years undergoing chemotherapy for early stage breast cancer (n=26). Patients were treated with chemotherapy (adriamycin, cyclophosphamide and paclitaxel) following surgery. Serum MIS, FSH, and E2 were measured before chemotherapy, at weeks 6, 12 , 36 and 52. Controls were 134 age-matched women with known fertility. Hormone levels were compared in the 2 groups at baseline. Trends during chemotherapy were assessed based on age and correlated with menstrual status in the breast cancer patients only.
 Results: Compared with age-matched controls, patients with breast cancer had similar baseline MIS levels (median 0.94 vs. 0.86 ng/ml, p>0.05). However, 29% of cancer patients had baseline MIS levels below the lower normal range (0.2 ng/ml). Serum MIS decreased significantly at 6 weeks and remained suppressed for 52 weeks (median 0.08 ng/ml at week 6, 0.05 ng/ml at week 12, 0.07 ng/ml at week 52, p<0.05 compared to baseline). At 6 weeks after treatment, 96% of the patients had MIS levels below 0.2 ng/ml. E2 levels decreased during chemotherapy, however, at 52 weeks, the levels returned to baseline levels. The percentage of women with E2 <30 pg/ml increased during chemotherapy and following chemotherapy. FSH levels increased 6 weeks after chemotherapy and returned to premenopausal levels by week 52, although only 33% of FSH levels were within premenopausal range (<10 IU/L) at week 52. At 52 weeks, 11 of 26 cancer patients (42%) remained amenorrheic. In women <35 years old, only 25% of women remained amenorrheic, whereas in women over 35 years, 50% were amenorrheic. Compared to women who regained menses, amenorrheic women had similar MIS values pre-chemotherapy and at 52 weeks post-chemotherapy.
 Conclusions: In women <40, chemotherapy decreases MIS rapidly and dramatically, and therefore early changes in MIS can not be used as a predictor of CIM. Although E2 levels generally recover, with 58% of young women regaining some menstrual function by 52 weeks, MIS levels remain abnormal, with all values remaining below the normal range of age-matched fertile women. Age continues to be an important factor for the recovery of ovarian function, specifically endocrine function, after chemotherapy.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1118.
Collapse
Affiliation(s)
- B Yu
- 1 Department of Obstetrics & Gynecology, Columbia University Medical Center, New York, NY
| | - R Lobo
- 1 Department of Obstetrics & Gynecology, Columbia University Medical Center, New York, NY
| | - KD Crew
- 2 Medicical Oncology, Columbia University Medical Center, New York, NY
| | - MJ Ferin
- 1 Department of Obstetrics & Gynecology, Columbia University Medical Center, New York, NY
| | - N Douglas
- 1 Department of Obstetrics & Gynecology, Columbia University Medical Center, New York, NY
| | - GS Nakhuda
- 1 Department of Obstetrics & Gynecology, Columbia University Medical Center, New York, NY
| | - DL Hershman
- 2 Medicical Oncology, Columbia University Medical Center, New York, NY
| |
Collapse
|
49
|
Capodice JL, Crew KD, Ortiz-Pride Y, Specht J, Braffman L, Fuentes D, Hershman DL. Survey of the prevalence and severity of sexual dysfunction in breast cancer patients. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.9557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
50
|
Crew KD, Shane E, Cremers S, McMahon DJ, Irani D, Sierra A, Hershman DL. High prevalence of vitamin D deficiency in a multi-ethnic cohort of premenopausal breast cancer patients. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.9583] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|